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Abstract 
Human β-defensins (hBDs) are a family of cationic peptides able to directly kill a wide 
range of microorganisms including bacteria, fungi and viruses. In addition to their 
antimicrobial activities, defensins also contribute to the modulation of both the host 
innate and adaptive immunity. In this project, we demonstrate that the αCD3/28 co-
stimulation of human CD4
+
 T cells in the presence of 10µg/ml hBD-2 or hBD-3 
together causes an up-regulation in numbers of CD4
+
CD69
+
CD25
+
 and CD4
+
CD69
-
CD25
+
 T cell subsets, indicating that the treatment of hBD-2 and 3 enhances CD4
+
 T 
cell activation. Consistent with this finding, proliferation assay using CFSE suggests 
that hBD-2 and hBD-3 treatment in vitro induces the proliferation of CD4
+
 T cells 
following by 96hrs culture. Analysis of expression of the regulatory T cells (Tregs) 
specific marker, FoxP3, reveals a shift in the CD4
+
CD127
-
CD25
+
 Treg subset at 18hrs. 
However, at the later time point, we found that the percentage of FoxP3
+
cells decreased 
in the CD4
+
CD127
-
CD25
+
 Treg population, whereas the presence of the FoxP3
+
CTLA-
4
+
 Treg subset increased. These data indicate that Treg suppressive function may be 
potentially defective following the co-incubation of purified T cells with either hBD-2 
or hBD-3 for 42hrs in vitro due to the apparent loss of FoxP3 expression. We further 
characterise the role of hBD-2 and hBD-3 in driving human CD4
+
 T cells polarisation. 
Our in vitro data suggests that treatment with hBD-2 and hBD-3 can not only induces 
effector T cell (Teff) differentiation into RORγt+T-bet+ (Th17/Th1) cells, but can also 
trigger the differentiation of Treg expressing RORγt and T-bet rather than the master 
controller of Treg function, FoxP3. This apparent plasticity of T cell phenotype allows 
them to convert from Treg to Th1/17-like effector T cell phenotype following 18hrs in 
culture. By 42hrs in culture, treatment with hBD-2 and hBD-3 induced both Teff cell 
and Treg cell differentiation towards the Th17-like phenotype. Compared with the 
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treatment with hBD-2, treatment with hBD-3 induced a more pronounced effect to 
increase levels of RORγt in CD4+ T cells. This elevated expression may, in turn, be 
responsible for the induction of higher IL-17A secretion. Consistent with this idea, it 
was found that treatment with hBD-3 but not hBD-2 was capable of inducing the higher 
level of secretion of IL-17A. Additionally, treatment with hBD-3 induced an increased 
expression of IL-6, which is capable of driving the differentiation of naïve T cells 
towards IL-17-producing Th17 cells. Functionally, using the Treg suppression assay, 
the data suggested that hBD-2 may dampen down Treg cell ability to induce 
suppression of Teff cell activity. Interestingly, co-culture with hBD-2 would also appear 
to increase Teff cell resistance to Treg immunoregulation in vitro. Further investigation 
using microarray gene analysis revealed chemokine C-C motif ligand 1 (CCL1) as 
potential genes responding to hBD-2 treatment. The blockade of CCL1 has been 
reported to inhibit Treg suppressive function. Thus, this study explored the function of 
these antimicrobial candidates in regulating CD4
+
 T cell plasticity which could result in 
hBD-2 and hBD-3 being able to regulate its own production, but also may regulate Treg 
and Teff cell development and function, thus strengthening the link between innate and 
adaptive immunity. 
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Chapter 1: Introduction 
1.1 Antimicrobial peptides 
Antimicrobial peptides (AMPs) play a crucial role in the innate immune system to 
protect the host from microbial infection (Wang, 2014). The majority of mammal AMP 
shave been identified in a variety of epithelial surfaces that directly interface with the 
environment such as skin, respiratory tract, intestine and reproductive tract(Mukherjee 
and Hooper, 2015).In human, the key AMP families are cathelicidins, such as LL-37, 
REG3 lectins and defensins (Kahlenberg and Kaplan, 2013, Mukherjee and Hooper, 
2015). 
 
Defensins form one family of AMPs which are a large group of 10 peptides in humans 
and 14 in mice (Muniz et al., 2012, Ouellette, 2005, Yamaguchi and Ouchi, 2012). 
These peptides are small proteins ranging in size from 2–4 kDa and they are all cationic 
peptides capable of directly responding to, and destroying, a wide range of microbial 
infections, such as bacterial, fungal and viral infections (Mukherjee and Hooper, 2015). 
The mammalian defensins constructed a multi-gene family which consist of different 
types of orthologs which are identifiable by their cysteine spacing, intramolecular 
disulphide bonds and genomic organization (Semple and Dorin, 2012). The defensin 
family comprises three sub-families, α-defensins, β-defensins and θ-defnsins (Jarczak et 
al., 2013).  
 
Generally, β-defensins have 6-cysteine motif and the molecular structure is constructed 
by disulphide bonds between Cys I-V, Cys II-IV and Cys III-VI, forming the typical β-
sheet structure of β-defensins (Wang, 2014, Semple and Dorin, 2012). In the human 
genome, computational analysis has shown that 11 β-defensin genes locate as a cluster 
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on chromosome 8p23.1 and the other β-defensin genes were found in clusters on 
chromosome 20p13, 20q11.1 and 6p12 (Schutte et al., 2002). The human β-defensin 2 
gene (hBD-2, DEFB2) is located in the p22–23 region of chromosome 8 which is close 
to the hBD-1 gene (DEFB1). This indicates that hBD-1 and hBD-2 genes were created 
by duplication of a single parental gene (Bals et al., 1999). The hBD-3 gene (DEFB3) is 
located close to DEFB2 gene, which is only about 13 kb from the DEFB-2 gene (Lehrer 
and Ganz, 2002). 
 
Most of β-defensin genes comprise of two exons. The exon 1 encodes the leucine-rich 
signal peptide, and the exon 2 encodes the mature peptide (Semple and Dorin, 2012). 
According to the sequence analysis of the murine β-defensin (mBD) gene cluster on 
chromosome 8, it was found that both of the DNA and protein sequence of the signal 
peptide encoded by exon 1 is highly conserved amongst mBD genes (Semple and Dorin, 
2012). In contrast to the signal peptide, the mature peptide encoded by exon 2 is not as 
well conserved as the signal peptide, leading to the diversity of β-defensin sequences 
which has developed as a response to selective pressure by a range of pathogens 
(Semple and Dorin, 2012, Jarczak et al., 2013). The molecular diversity can also reflect 
the different antimicrobial activity and tissue distribution of β-defensins, which suggests 
that β-defensins can provide the host with a range of different responses to a variety of 
pathogens and also may modulate different immune functions (Jarczak et al., 2013). 
 
In recent years, the biological functions of β-defensins have been not only restricted in 
their antimicrobial activities but also extended to immunomodulation and their 
involvement in other processes, such as cancer and wound healing. In this study, we 
will focus on the role of hBD-2 and hBD-3 in human CD4
+
 T cell polarization. 
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Figure 1.1 The solution structure of hBD-2 (PDB ID: 1FQQ) (Sawai et al., 2001) and 
hBD-3 (PDB ID: 1KJ6) (Schibli et al., 2002). 
 
1.2 Multifunctional role of Human β-defensins in immune system 
1.2.1 Antimicrobial activity of hBDs 
hBD-2 was originally purified from psoriatic skin lesions using Escherichia coli affinity 
column (Harder et al., 1997). The antimicrobial activity of hBD-2 is mainly against 
Gram-negative bacteria, yeasts, and HIV but not against HSV (Winter and Wenghoefer, 
2012, Ganz, 2003). Like hBD-1, the antimicrobial activity of hBD-2 is inhibited by high 
concentrations of NaCl (20mM to 150 mM) (Bals et al., 1998), although the 
concentration of both salt and the peptides can influence its antimicrobial activity 
(Jarczak et al., 2013). Unlike hBD-2, hBD-3 is effective in killing Gram-positive 
vancomycin-resistant Enterococcus faecium and Staphylococcus aureusas well as the 
yeast Candida albicans at physiological salt concentrations (Harder et al., 2001). These 
findings may indicate that the antimicrobial activity of defensins could be regulated by 
salt concentrations under different infectious or inflammatory conditions.  
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In contrast to hBD-1 which is constitutively expressed by epithelial cells, the expression 
of hBD-2 and hBD-3 is triggered during infections or following various inflammatory 
stimuli, such as activation of IL-1β (Ramasundara et al., 2009, Doss et al., 2010). The 
expression of the hBDs in epithelial cells is mediated by Nucleotide-binding 
Oligomerization Domain-containing Proteins (NODs) as a receptor recognizing 
intracellular bacterial that, in turn, activates Nuclear Factor (NF)-κB to trigger gene 
expression of β-defensins (Voss et al., 2006). Interestingly, it was found that up-
regulation of hBD-2 expression was induced through a NOD1-dependent signalling 
pathway, while the expression of hBD-3 was enhanced by a mechanism that is mediated 
through a NOD-independent, EGFR-mediated pathway (Boughan et al., 2006).  
 
The expression of hBD-2 was significantly increased by human colonic epithelial cell 
lines HT-29 and Caco-2 cells following exposure to pro-inflammatory levels of IL-1α 
and/or enteroinvasive E. coli (O29:NM), suggesting that hBD-2 plays an crucial role in 
the pathology of colitis and colitis-associated growth of microflora (Ho et al., 2013). 
Additionally, George et al. (2003) demonstrated that infection by Helicobacter pylori 
up-regulated hBD-2 and hBD-3 mRNA and protein expression in gastric cell lines both 
in vitro and in vivo, and hBD-2 as well as hBD-3 display strong antimicrobial activity 
against H. pylori. Further investigation by Paolillo et al. (2009) indicated that the 
mRNA and protein expression of hBD-2 were significantly enhanced in Caco-2 cells 
when exposed to Lactobacillus plantarum in a time and dose-dependent manner. 
 
Additionally, the reduction of murine β-defensin 10 expression caused the impaired 
regulation of growth of several major components of the intestinal microbiota, such as 
Bacteroides fragilis, E. coli, E. faecalis, and C. albicans (Peyrin-Biroulet et al., 2010). 
Defb1 knockout mice were found to have increased level of Staphylococcus species in 
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their normally sterile urine (Morrison et al., 2002) and a defective ability to inhibit 
Haemophilus influenza growth in the airway (Moser et al., 2002). These findings 
demonstrate the importance of β-defensins in the innate defence against infections. 
 
Collectively, hBDs function as antimicrobial agents and their expression is regulated by 
the signalling induced following exposure to both inflammatory and bacterial stimuli. 
However, the in vitro antimicrobial activity of β-defensins may not represent the full 
function in vivo, as the peptide concentrations required for in vitro antimicrobial activity 
are higher than those that are observed in vivo(Semple and Dorin, 2012). Despite the 
difference between in vitro culture condition and in vivo physiological conditions, it is 
suggested that β-defensins can not only inhibit bacteria growth by directly interacting 
with bacteria, but also modulate both innate and adaptive immunity(Semple and Dorin, 
2012).  
 
1.2.2 hBDs regulate pro-inflammation in innate immune responses 
In addition to their antimicrobial activities against both Gram-positive and Gram-
negative bacteria, defensins are also capable of mediating inflammatory innate immune 
reactions. These mediators are also known to possess chemoattractant activities able to 
recruit and activate other leukocyte populations into the inflamed area. (Oppenheim and 
Yang, 2005). Moreover, hBD-2 is capable of inducing recruitment of mast cells and 
neutrophils (Niyonsaba et al., 2002, Niyonsaba et al., 2004). In addition to hBD-2, 
mBD-14 (DEFB14), the mouse ortholog of hBD-3, was also shown to chemoattract 
both human and mouse CCR6-expressing cells (Taylor et al., 2008, Rohrl et al., 2008). 
hBD-3 was also demonstrated to suppress the apoptosis of neutrophils via binding to 
CCR6 at the neutrophil cell surface, increasing the expression of the anti-apoptotic 
protein Bcl-xL which, in turn, inhibits caspase-3 activity (Nagaoka et al., 2008). 
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However, hBD-3 and hBD-4 also were also shown to induce chemoattraction of 
macrophages which are not CCR6
+
, suggesting alternative receptors other than CCR6 
may be involved in the interaction with β-defensins. Rohrl et al. (2010) demonstrated 
that it was the CCR2 receptor which mediates the migration of monocytes and 
macrophages in response to hBD-2 and hBD-3. Additionally to the interaction with 
CCR2 and CCR6, β-defensins also have been demonstrated to interact with Toll-like 
receptors (TLRs) on antigen presenting cells (APCs) (Dorin and Barratt, 2014). hBD-3 
was also reported to induce the expression of the co-stimulatory molecules CD80, 
CD86, and CD40 on monocytes and myeloid dendritic cells (DCs), and interestingly, 
this up-regulation in expression is dependent upon TLR1 and TLR2 ligation 
(Funderburg et al., 2007), whilst mBD-2 enhances the activation of DCs in a TLR4-
dependent manner (Biragyn et al., 2002). hBD-3 is also reported to increase the protein 
level of pro-inflammatory cytokines, including IL-1β, IL-6 and IL-8, in human 
monocytes via TLR1/2 (Funderburg et al., 2011). Alternatively, hBD-3 is capable of 
blocking CXCR4 activation by CXCL12 (Feng et al., 2013). In addition, hBD-2, hBD-3 
and hBD-4 have been previously shown to induce pro-inflammatory mediators in 
keratinocytes including macrophage inflammatory protein-3α (MIP-3α), monocyte 
chemoattractant protein-1 (MCP-1), RANTES, IL-6, IL-10 and IP-10, through the G-
protein and phospholipase C (G protein-PLC) signalling pathway (Niyonsaba et al., 
2007).  
 
As well as their pro-inflammatory role, β-defensins have also been reported to be 
suppressors of inflammation as well. Semple et al. (2010) demonstrated that hBD-3 and 
mBD-14 could inhibit TNF-α and IL-6 accumulation in human and mouse primary 
macrophages, respectively. They also showed that in the presence of hBD-3, the 
stimulation of macrophages by CD40/IFN-γ was significantly reduced in vivo (Semple 
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et al., 2010). Further investigation supported the finding that hBD-3 inhibits the 
transcription of pro-inflammatory genes in TLR4-stimulated macrophages (Semple et 
al., 2011). It is suggested that hBD-3 down-regulated the protein levels of pro-
inflammatory cytokines, such as IL-6 and IL-12p40, and cell surface molecules, such as 
CD40 and CD86. In addition, hBD-3 reduces NF-κB signalling in cells transfected with 
MyD88 or TRIF, which are down-stream of TLR4 signalling, suggesting that the 
Myd88 and TRIF are the downstream targets of hBD-3 mediated suppression of the 
activation of macrophages (Semple et al., 2010). 
 
Collectively, these findings suggest that β-defensins are able to regulate both pro- and 
anti-inflammatory immune responses by interacting with different receptors on several 
different types of immune cells. 
 
1.2.3 hBDs regulate pro-inflammation in T-cell-mediated adaptive immune response 
Recent studies have demonstrated that hBDs are also capable of regulating the adaptive 
immune response. Yang et al. (1999) demonstrated that hBD1–3 induced 
chemoattraction of CD4
+
 memory T cells and immature DCs through interaction with 
CCR6. Although hBD-2 has a lower affinity than CCL20 for the interaction with CCR6, 
both ligands can compete for binding to CCR6. Ghannam et al. (2011) demonstrated 
that hBD-2 was able to mediate the migration of the pro-inflammatory Th17 cell, in an 
in vitro model using induced inflammation in endothelial cells under flow conditions. 
Their data also showed that the Th17 derived cytokines, IL-17 and IL-22, could induce 
the secretion of hBD-2 by epidermal keratinocytes leading to the increase of 
inflammation. 
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As mentioned briefly above, in addition to the capability of hBDs to act as a 
chemoattractant to T cells, Boniotto et al. (2006) found that hBD-1, 2 and 3 are all 
capable of up-regulating the secretion of a variety of cytokines, such as IL-6, IL-8 and 
IL-10, and chemokines, such as MCP-1 by human peripheral blood mononuclear cells 
(PBMCs). These defensins also showed different abilities to induce the secretion of 
selected cytokines and chemokines. Following this study, Kanda et al. (2011) 
demonstrated that hBD-2 regulated cytokine mRNA expression and protein secretion by 
human CD3
+
 T cells in vitro. Their data suggested that hBD-2 induced TNF-α, IFN-γ, 
IL-1β, IL-6, IL-10, and IL-22 production by these CD3+ T cells but inhibited IL-17 
production. Additionally, the induction of cytokine production was found to be due to 
the enhanced expression of SOCS3 and the suppressed phosphorylation of STAT3 by 
hBD-2 treatment in αCD3/28-stimulated T cells (Kanda et al., 2011). These effects 
were suggested to be induced by hBD-2 via PTX-sensitive GPCR (Kanda et al., 2011). 
Additionally, investigation by Meisch et al. (2013) indicated that hBD-3 causes STAT1 
tyrosine phosphorylation in human CD3
+
CD45RO
+
 T cells.  
 
Further investigation suggested that hBD-2 induced IL-22 and oncostatin M in human 
CD3
+
 T cells (Kanda and Watanabe, 2012). The induction of T cell cytokines by hBD-2 
treatment provides the evidence that treatment with hBD-2 potentially influences T cell 
differentiation following activation. Recent studies by Agatha Schwarz‟s lab 
demonstrated that the treatment of T cells with murine β-defensin 14 (mBD-14) is 
capable of inducing a regulatory phenotype in CD4
+
 T cells. They used a murine model 
of contact hypersensitivity (CHS) induced by painting 2,4-dinitro-1-fluorobenzene 
(DNFB) on the skin of a mouse to test the suppressive function of mBD-14 on tissue 
inflammation. They found that the injection of mBD-14 before sensitization can protect 
the mice from the ear-swelling response compared to the non-injected control. 
9 
 
Additionally, the transfer of the splenocytes and lymph node cells obtained from mBD-
14-treated mice can significantly suppress CHS response in the recipient mice (Navid et 
al., 2012). Finally, they showed that mBD-14 treatment in vitro can induce the 
expression of FoxP3, CTLA-4, CD62L and neuropilin on CD4
+
CD25
-
 T cells, which 
are considered as conventional T cells (Navid et al., 2012). These studies suggest that 
mBD-14 can induce regulatory phenotypes in vivo. More recently, a similar regulatory 
effect was demonstrated using an EAE mice model. The injection of mBD-14 into mice 
before immunization can significantly reduce the clinical score of experimental 
autoimmune encephalomyelitis (EAE), suggesting that mBD-14 treatment can induce 
Treg cell development to inhibit the inflammation in central nervous system (Bruhs et 
al., 2015). Interestingly, this regulatory effect induced by mBD-14 in CD4
+
CD25
-
 T cell 
is found to be IL-10-dependent because the T cells obtained from IL-10
-/-
 mice could 
not protect the recipient mice from ear-swelling (Navid et al., 2012).  
 
Additionally, a recent study by Tomalka et al. (2015) demonstrated that the murine β-
defensin, mBD-1, mediates the mucosal defense against C. albicans. They found that 
mBD-1 deficient mice exhibit impaired neutrophil infiltration which leads to the 
increased C. albicans infection. On the other hand, the deficiency of mBD-1 causes 
significant down-regulation of IL-1β, IL-6 and IL-17, suggesting defective Th17 lineage 
differentiation which is required in antifungal immune response against C. albicans 
infection. 
 
In summary, these studies suggest a role for β-defensins in regulating T cell 
development and function. In respect to the functional diversity of human T cells in 
particular, it is of great interest to investigate the effect of hBD-2 and 3 in driving 
human CD4
+
 T helper cell differentiation. 
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Table 1.1 The antimicrobial activities and immunomodulatory function of hBD-2 and hBD-3. 
 hBD-2 hBD-3 References 
Expression sites Epithelium of tracheal, kidneys (also 
fetal kidneys),bladder, kernel, uterus, 
prostate, stomach, small intestine, 
liver, pancreas, thymus, marrow, 
leucocytes , cells forming keratin, and 
the skin; 
Expressed following  microbial 
infection and inflammation. 
Keratinocytes, tonsils, skin, 
esophagus, placenta, trachea, uterus, 
kidney, thymus, adenoid, pharynx, 
tongue, heart of adults, fetal thymus, 
skeletal muscle, gums, tongue, 
mucosa of cheeks and lips, dental 
follicle and pulp. 
Expressed following  microbial 
infection or secretion of inflammatory 
cytokines, such as IL-1β. 
(Jarczak et al., 2013) 
Antimicrobial activities Antimicrobial activity against Gram-
negative bacteria, yeasts, HIV and 
HPV; 
Antimicrobial activity can be inhibited 
by NaCl 
Antimicrobial activity against Gram-
positive bacteria, Gram-negative 
bacteria, yeasts, HIV and HPV; 
Antimicrobial activity is resistant to 
high NaCl concentration. 
(Jarczak et al., 2013, Wang, 2014) 
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Immunomodulatory function Chemotactic activity for monocytes, 
macrophages, neutrophils and 
immature dendric cells; 
Induces phosphorylation of JNK, 
ERK, and Akt in human CD3
+ 
T cells; 
Suppresses phosphorylation of STAT3 
and enhances expression of SOCS3 in 
αCD3/28-stimulated human 
CD3
+
Tcells; 
Enhances cytokine secretion and 
mRNA expression. 
Chemotactic activity for monocytes, 
macrophages, neutrophils and 
immature dendric cells via CCR6, 
CCR2 or CXCR4; 
Inhibits TLR4 downstream signaling, 
such as MyD88 and TRIF, in 
macrophages; 
Induces STAT1 phosphorylation, 
tyrosine phosphatase activity, and 
cytokine synthesis in human CD3
+
 T 
cells. 
(Jarczak et al., 2013, Semple et al., 
2011, Semple et al., 2010, Meisch et 
al., 2013, Kanda et al., 2011) 
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1.3 Research aims 
Recent studies have suggested a role for defensins in Treg development (Navid et al., 
2012), however the effect of hBD-2 and 3 on human CD4
+
 T helper cell differentiation 
is not fully explored. Thus, the aim of this study is to investigate the role of hBD-2 and 
hBD-3 in driving human CD4
+
 T cell activation, proliferation and differentiation.  
 
1.4 Research objectives 
 To investigate the effect of hBD-2 and hBD-3on CD4+ T cell activation and 
proliferation using human whole PBMCs; 
 To investigate the effect of hBD-2 and hBD-3 on purified human CD4+ T cell 
activation and proliferation; 
 To characterize the polarization of purified human CD4+ T cells in the presence 
or absence of hBD-2 and hBD-3 and investigate cytokine production in the cell 
culture; 
 To assess the suppressive function of hBD-2 pre-treated Treg cells and the 
resistance of hBD-2 pre-treated Teff cells from Treg suppression. 
 To investigate the transcriptome profile of human CD4+ T cells after treatment 
with of hBD-2 using microarray analysis. 
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Chapter 2: Methodology 
 
2.1 Ethical approval 
This study has been reviewed and approved by the NHS City Road and Hampstead 
Research Ethics Committee (Appendix 2.1) as well as the University Research Ethics 
Committee of University of East London (Appendix 2.2). Human venous blood samples 
were collected with written consent from healthy volunteers according to the NREC 
approvals (Ref: 13/LO/0296). 
 
2.2 Antibodies and reagents 
Synthesized peptides of hBD-2 and hBD-3 were purchased from Severn Biotech (UK). 
Anti-human CD3 (Clone: OKT3) and anti-human CD28 (Clone: CD28.6) antibodies 
were purchased from eBioscience. The following eBioscience mAbs were used in flow 
cytometry: FITC-conjugated anti-human CD69 (Clone: FN50); PE-conjugated anti-
human CD25 (Clone: BC96); PE-conjugated anti-human CD127 (Clone: eBioRDR5); 
PE-Cyanine7-conjugated anti-human CD4 (Clone: RPA-T4); PE-Cyanine7-conjugated 
anti-human T-bet (Clone: 4B10); allophycocyanin (APC)-conjugated anti-human FoxP3 
(Clone: 236A/E7); PE-conjugated anti-human RORγt (Clone: AFKJS-9). 5-(and 6)-
Carboxyfluorescein diacetate succinimidyl ester (CFSE; eBioscience) was used to trace 
cell proliferation. 
 
2.3 Isolation and activation of human PBMCs 
Initially, 50ml of peripheral blood was taken from healthy donors using heparinized 
vacutainer tubes. PBMCs were isolated by density gradient centrifugation using the 
Histopaque 1077 (Sigma, USA). Blood samples were diluted 1:1 (v/v) with AIM-V 
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medium (Gibco, UK). The diluted blood were carefully layered onto 10ml of 
Histopaque 1077 in a sterile conical centrifuge tube and then centrifuged at 400×g 
without break for 30mins. After centrifugation, the interface containing the whole 
PBMCs was carefully taken and moved into a new centrifuge tube. Subsequently, the 
cells were washed by medium twice to remove the excess Histopaque. After washing, 
the isolated PBMCs were seeded at 2.0×10
6
 cells/ml in 96-well plates and stimulated 
with soluble anti-human CD3 (0.005μg/ml) and anti-human CD28 (0.005μg/ml) 
antibodies (eBioscience) in the presence or absence of 1, 3 and 10µg/ml hBD-2 in 200µl 
AIM-V medium. Cell cultures were incubated at 37℃, 5% CO2. After 18hrs and 42hrs, 
PBMCs were assayed for cell surface marker expression and a range of cytoplasmic 
markers including CD4, CD69 and CD25 using flow cytometry. 
 
2.4 Purification of human CD4+ T Cells 
CD4
+
 T cell were isolated using EasySepTM human CD4
+
 T cell enrichment kit 
(StemCell, UK) according to the manufacturer‟s instruction. Human PBMCs were 
suspended in a sterile polystyrene tube with recommended buffer (PBS with 2% FCS). 
Cell suspensions were incubated with antibody cocktail (CD8, CD14, CD16, CD19, 
CD20, CD36, CD56, CD66b, CD123, TCRγ/δ, glycophorin A) for 10mins. Then, 
magnetic beads were added into cell suspension and incubated for 5mins. Finally, the 
tube was inserted into magnet. After 5mins incubation, the fraction of purified CD4
+
 T 
cells was poured into a new sterile tube. These isolated CD4
+
 T cells were stimulated 
using plate bound anti-human CD3 antibodies (0.1μg/ml) and soluble anti-human CD28 
antibodies (2μg/ml), according to the published methodology (Kanda, 2011, Kanda and 
Watanabe, 2012). 
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2.5 Enzyme linked immunoabsorbent assay (ELISA) 
For assay of IL-2, IL-6, IL-10 and IL-17A secretion, supernatants of cell culture were 
collected and the cytokine concentrations were determined by ELISA Ready-Set-Go 
kits (eBioscience, UK) according to the manufacturer‟s instructions. Firstly, 96-well 
plates were coated with capture antibodies overnight at 4℃. Then, the wells were 
washed using ELISA wash buffer (1× PBS, 0.05% Tween-20) to remove unbound 
antibody and blocked using 1× ELISA/ELISPOT Diluent from the kit for 1hr. After 
washing, 100µl of diluted supernatant samples along with a serial dilution of 
recombinant cytokine protein were added and the plate was incubated at 4℃ overnight 
in order to get the maximal sensitivity. After incubation, the samples were aspirated and 
the plate was washed using ELISA wash buffer. Detection antibody against each 
individual cytokine was added and incubated at room temperature for 1hr. Then, the 
plate was washed again and the diluted Avidin-HRP was added and incubated for 
30mins. After washing, the substrate was added and the colour was allowed to develop 
for 15mins at room temperature. After 15mins incubation, the stop solution was added 
to the plate (2N H2SO4) to stop the reaction. Finally, The plates were read using the 
Thermo Multiskan plate reader (Thermo) at 450nm. The actual values for analysis were 
obtained by subtracting the values obtained at 570nm. 
 
2.6 Cell Proliferation assay 
Isolated PBMCs were washed twice with PBS to remove fetal calf serum (FCS) in the 
culture. Then, cells were suspended in PBS at 2.0×10
6
 cells/ml in PBS. 
Carboxyfluoroescein diacetate succinimidyl ester (CFSE) was added (5mM) to a final 
concentration of 5µM, vortexed gently and the suspension allowed sitting for 15mins in 
37℃ incubator. To stop further labelling of the cells, an equal volume of 5% FCS/PBS 
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was added to the cell suspension. The cells were centrifuged for 5min, 400×g. The 
supernatant was discarded and the cell pellet resuspended to obtain a single cell 
suspension. Cells were washed twice by suspending in 10ml of 2% FCS/PBS. Cells 
were centrifuged for 5min, 400×g. Finally, the labelled cells were resuspended in AIM-
V at 2.0×10
6
 cells/ml. Where described, IL-2 (0.02μg/ml) was added to promote T cells 
proliferation. 
 
2.7 Flow cytometry 
Cells were prepared and incubated with fluorescence-conjugated antibodies for cell 
surface markers, such as CD4, CD69 and CD25. Briefly, cells were washed and 
suspended in 50µl of FACS buffer (PBS containing 2% FCS). Then, 50µl of antibody 
cocktail was added into each cell suspension. After gently flicking, the cell suspension 
was incubated on ice for 30mins. Then, cells were washed using FACS buffer and were 
then analysed using an Accuri C6 Flow Cytometer (BD Bioscience, UK). For the 
staining of intracellular transcriptional factors, FoxP3, T-bet and RORγt, intracellular 
staining was performed using FoxP3/Transcription Factor Staining Buffer Set 
(eBioscience, UK). After labelling with surface antibodies as described earlier, cells 
were initially fixed and permeabilized using Fixation/Permeabilization solution and 
stained with selected antibodies in 1× Permeabilization Buffer. After staining, cells 
were washed and resuspended in FACS buffer ready for analysis using the Accuri C6. 
 
2.8   RNA extraction 
RNA samples were isolated and purified using PureLink RNA Mini Kit (12183018A, 
Life Technologies). Cultured human CD4
+
 T cells were collected and pelleted in RNase 
free tubes. After removing the supernatant, lysis buffer containing 1% β- 
mercaptoethanol was added in an appropriate amount according to the cell count. The 
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cell lysate was processed in order to extract RNA according to the manufacturer‟s 
instruction in which a step of DNase on column digestion was also applied using 
PureLink DNase set (Life technologies, UK). The quality and quantity of RNA samples 
was determined using the Nanodrop ND-1000 spectrophotometer (Nanodrop 
technologies, Wilmington, US). Samples with an absorbance of 260/280nm ratio 
between 1.8 and 2.1 were considered as accepted quality to be used in downstream 
experiments. The isolated RNA samples were stored at -80℃. cDNA was synthesised 
using the iScript cDNA Synthesis Kit (Bio-Rad, CA, USA). RNA samples were 
extracted as described earlier. 300-400ng RNA was added in the reaction to make up a 
total volume of 20μl. The other components, such as Oligo(dt) primers, reverse 
transcriptase, are provided by the kit. The cDNA synthesis was performed using the 
Bio-rad T100TM Thermal Cycler (Bio-Rad, Inc., US). The reaction program was set as 
it is suggested in the manufacturer‟s reaction protocol. cDNA samples were stored at -
20℃. 
 
2.9 Micro-array assay 
An ethanol precipitation step was carried out in order to further purify RNA samples. 
RNA samples were applied to an Affymetrix HuGene Exon Expression Microarray 
Chip. Poly-A controls were used to monitor the entire target labelling process. Poly-A 
controls were dap, lys, phe, thr. Hybriziation controls were bioB, bioC, bioDn, creX. 
The signal intensities of the hybridization control probes are presented in Appendix 2.3. 
As it is shown in Appendix 2.3, the profiles of all samples are similar, indicating good 
hybridization and washing of the arrays. CEL files were produced and then analysed 
using Agilent GeneSpring GX 13 software. The data was normalized using the 
GeneSpring GX 13 software with the Robust Multi Array (RMA) algorithm and. 
Statistical analysis was performed using t test. p values less than 0.05 were considered 
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to be significant. In addition, fold changes of gene expression of more than 1.5 were 
considered biologically relevant. Principal Component Analysis (PCA) was carried out 
as described in Furmanski et al. (2013). Briefly, CEL files were analysed for PCA using 
the CRAN package (Bioconductor, U.S). Genes identified from GeneSpring and PCA 
was verified using qRT-PCR. 
 
2.10 Quantitative RT-PCR 
Relative gene expression levels of selected target genes were measured using 
quantitative real-time PCR (qPCR). RNA extraction and cDNA synthesis were 
performed using the same method as described earlier. qPCR were performed using the 
iTaq UniverSYBR Green RT-PCR kit (Bio-rad, UK) following the manufacturer‟s 
protocol. The house-keeping gene, human hypoxanthine guanine phosphoribosyl 
transferase 1 (Hprt1), was used as internal standard for the quantification of template as 
well as the normalisation of target gene expression. Amplification of Hprt1 was 
quantified using a dilution series of neat cDNA, 1:10, 1:100, 1:1000 and 1:10000 
prepared from stimulated control CD4
+
 T cells RNA and the relative standard curve for 
the gene of interest was generated by a 1:10 serial dilution of RNA prepared from 
cultured CD4
+
 T cells in the presence or absence of hBD-2 (10µg/ml) or hBD-3 
(10µg/ml). The efficiency of the qRT-PCR was determined for each gene with the slope 
of a linear regression model (Pfaffl, 2001). The efficiencies (E) were calculated 
according to the equation: E= (10
(-1/slope-1)
 ×100). 
 
The primers used for the reaction are listed below in Table 2.1. All primers used were 
purchased from Quantitech (Qiagen, UK). The primer sequences are protected by 
Qiagen. Each reaction contained approximately 100ng of cDNA, 300nM of forward and 
reverse primers, 10μl of SYBR green super-mix (containing, iTaq DNA polymerase, 
19 
 
dNTPs, MgCl2). The reaction was made up to 20μl using nuclease free water (Qiagen 
Inc., US) in a 96 well plate (Thermo Scientific, U.K). Data analysis was performed 
according to using standard curve method (Bolha et al., 2012). The calculation of 
relative expression is shown in Appendix 2.4. Gene expression levels were first 
normalized to the expression levels of the Hprt1 and then calculated relative to the 
normalized gene expression in the stimulated control (Maine et al., 2014).  
qRT-PCR reaction was performed under the recommended conditions for each primer 
used according to the manufacturer‟s protocol: initial denaturation at 95oC, for 30s 
followed by 40 cycles of denaturation at 95
o
C for 30s and annealing at 60
o
C for 30s. In 
each experiment, an additional programme for the detection of melting curve was 
performed in order to check the melting temperatures of the products to assess primer-
dimer formation and confirm the product size was as expected (Appendix 2.3). 
 
Table 2.1  Primers used in RT-PCR experiment 
Target genes Primer Ref. No. 
Ccl1 QT00203154 
Ctla4 QT01670550  
Il23r QT00032914 
Il21 QT00038612 
Hprt1 QT00059066 
 
 
2.11 Treg/Teff sorting and Treg suppression assay 
Purified human CD4
+
 T cells were stained with anti-CD4-Pe-Cy7, anti-CD25-APC and 
anti-CD127-PE antibodies before FACS sorting. Then, CD4
+
CD25
+
CD127- Treg cells 
and CD4
+
CD25-CD127
+
 Teff cells were sorted using BD FACSAria III. After sorting, 
target Teff cells were stained with CFSE using the method described previously. Then, 
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CFSE labelled target Teff cells and Tregs were seeded in separate wells at 2.0×10
6
 
cells/ml and incubated in the presence or absence of hBD-2 for 4hrs. After hBD-2 
treatment, Teff and Treg cells were collected and washed with fresh medium twice and 
target Teffs were cultured alone at 5.0×10
4
 cells/well or co-cultured with Tregs at a 
Teff/Treg ratio 1:1 in 96-well plate. Teffs were stimulated using αCD3/28 antibody 
coated beads (Dynabeads, Life Technologies) at a bead/cell ratio 1:10. Proliferation of 
Teffs was assessed by flow cytometry following 4 days in culture. 
 
2.12 FACS gating strategy 
PBMCs were stained and analysed using flow cytometry (Accuri C6, BD). To exclude 
dead cells, a plot of forward scatter (FSC-A) vs. side scatter (SSC-A) was set at the 
beginning of analysis. Lower granularity on SSC-A and FSC-A indicates dead cells. In 
PBMCs, CD4 was used as the first marker and it is plotted against the SSC gated as 
shown in R1. Cells were then analysed for the expression of T cell activation markers, 
CD69 and CD25, within the CD4
+
 T cell gate. In the case of purified CD4
+
 T cells, T 
cell activation was analysed also using CD69 and CD25 similar to the PBMCs. In 
addition to activation, the Treg population was gated as CD4
+
CD25
+
CD127- subset, 
whereas the activated effector T cell (Teff) population was gated as 
CD4
+
CD25
+
CD127
+
 subset. The expression of transcription factors, such as FoxP3, T-
bet and RORγt was analysed using the gates for Treg cells or activated Teff cells. 
 
2.13 Statistical analysis 
Statistical analysis was performed using the Student t Test for statistical testing between 
two groups, or One-way ANOVA for three groups. Column graphs were generated by 
GraphPad Prism 5. Dot-plots and peak-plots were generated by Accuri CFlow software 
(BD Bioscience, UK). Differences between the means and the stimulated control value, 
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with p values of 0.05 or less, were considered statistically significant. Unless otherwise 
stated, the figures in the results show one representative experiment of at least three 
independent experiments. 
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Chapter 3: Effects of hBD-2 on whole PBMCs population 
 
3.1 Introduction 
β-defensins were initially described as peptides with only direct antimicrobial activity 
and therefore were regarded as an essential innate immune component protecting the 
host from infection (Jenssen et al., 2006, Harder et al., 2007). Biragyn et al. (2002) 
were considered as the first to report that defensins may play a role as a mediator in 
both the innate and the adaptive immune response. Their studies demonstrated that 
mBD-2 up-regulates co-stimulatory molecules on immature DCs by interacting with 
TLR-4, thereby inducing DC maturation. Additionally, hBD-3 as well as LL-37 was 
shown to exhibit chemotactic activity for monocytes, immature DCs, neutrophils and T 
cells (Doss et al., 2010).  
 
It has also been shown that the closely related, α-defensins cannot only regulate the 
maturation and differentiation of leukocytes but also act as chemotactic factors. In 
particular, the α-defensins, HNP1–3, have been reported to control the maturation of 
human monocyte-derived DCs and regulate the maturation of these cells as judged by 
CD83, CD86 and HLA-DR expression in a dose dependent manner (Rodriguez-Garcia 
et al., 2009).  
 
In addition to HNP1, hBD-1 was also suggested to be chemotactic for monocyte-
derived DCs by inducing the activation of these cells and production of pro-
inflammatory mediators in these cells (Presicce et al., 2009). Moreover, Boniotto et al. 
(2006) revealed that human PBMCs treated with hBD-2 can up-regulate secretion of a 
number of cytokines, such as IL-6, IL-8 and IL-10 by these cells in vitro. These studies 
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reveal the fact that defensins may play a crucial role in regulating both the innate and 
adaptive immune responses. 
Dysregulated expression of the defensins may also lead to the development of 
pathologies. The over-expression of hBD-2 in keratinocytes is considered to participant 
in the induction of autoimmune pathology, such as chronic psoriasis by inducing the 
infiltration of IL-17-producing T cells into psoriatic skin (Lowes et al., 2014). Kanda et 
al. (2011) detected elevated levels of hBD-2 in serum from patients suffering from 
psoriasis which correlated in a positive fashion with levels of TNF-α, IFN-γ, IL-1β, IL-
6, IL-10 and IL-22, but were inversely correlated with IL-17 levels. Consistent with this 
finding, they found that mRNA levels of TNF-α, IFN-γ, IL-1β, IL-6, IL-10 and IL-22 
were significantly higher in hBD-2 treated CD3
+
 T cells in contrast to the untreated 
control, suggesting that the defensins were working to up-regulate the pro-inflammation 
which may lead to autoimmunity. 
 
β-defensins have also been shown to regulate the development of Tregs. The mouse 
homolog of hBD-2 and hBD-3, Defb14, has been indicated to be capable of switching 
CD4
+
 effector T cells into Treg cells with an accompanying increase in secretion of the 
immunosuppressive cytokine, IL-10 (Navid et al., 2012). Moreover, mBD-14 has been 
shown to be able to direct CD4
+
CD25- T cells into a regulatory phenotype by up-
regulating the expression of FoxP3 and CTLA-4 in these cells (Navid et al., 2012). 
 
In this chapter, we investigate the immune-modulatory effects of hBD-2 on human 
peripheral blood derived T cells in the culture of whole PBMCs. Synthetic hBD-2 
peptides were used at a range of different doses and were added to the cultures of 
PBMCs together with soluble αCD3/28. Any effect of hBD-2 on T cell activation, 
proliferation and apoptosis of the CD4
+
 T cells was analysed using flow cytometry. We 
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also investigated the development of CD4
+
CD25
high
 Treg cells by analysing the 
expression of the marker for Tregs, FoxP3. 
 
3.2 Results 
3.2.1 Treatment with hBD-2 up-regulates the number of percentage of FoxP3+ cells in 
CD4
+
CD25
high
 T cells at 18hrs, but down-regulates FoxP3
+
 cells at 42hrs. 
It has been suggested in several studies that the commensal microbiota in intestine plays 
an important role in facilitating the immune system, including the generation of an 
appropriate environment for the development of Tregs (Brenchley and Douek, 2012, 
Muniz et al., 2012, Ostaff et al., 2013). Antimicrobial peptides (AMPs) are an essential 
component of this environment. In this chapter, we have selected to study hBD-2 in 
order to assess what impact this AMP might have on the adaptive immune response and 
in particular the emergence of Tregs. 
 
Tregs represent a distinct phenotype of T cells that express CD4, α chain of IL-2R 
(CD25), and FoxP3 (Josefowicz et al., 2012). FoxP3 has been demonstrated as a 
transcriptional factor specifically expressed in CD4
+
CD25
high
 Tregs (Hori et al., 2003). 
It has been demonstrated that FoxP3 functions as a key regulatory gene for the 
development of Tregs, as retroviral gene transfer of FoxP3 converts naive T cells into a 
Treg phenotype similar to that of naturally occurring Tregs (Navid et al., 2012, Bilate 
and Lafaille, 2012).  
 
Additionally, CD69 is a type II C-lectin membrane receptor barely expressed on resting 
lymphocytes but then rapidly induced on effector T cells upon cell activation which 
makes it a good marker of choice to measure early activation of T cells (Gonzalez-
Amaro et al., 2013). Recent studies have suggested that the cytoplasmic tail of CD69 
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can interact with the transcriptional factor STAT5, which is an essential mediator of IL-
2 signalling in T cells. IL-2 enhances Treg function via increased expression of FoxP3, 
whilst inhibits Th17 differentiation and IL-17 production through the inhibition of 
STAT3 signalling (Gonzalez-Amaro et al., 2013).  
 
In order to investigate the effect of hBD-2 treatment on the development of Tregs 
within a PBMC mixed cell culture, expression of CD4 and CD25 was used to identify 
putative Tregs and then intracellular expression of FoxP3 was analysed in this gated 
population. Upon incubation of PBMCs with 10ug/ml hBD-2 at 18hrs, a 50% increase 
in levels of FoxP3 fluorescence intensity was observed in CD4
+
CD25
+
 T cells (Figure 
3.1A, upper left). In addition, the percentage of CD4
+
CD69
+
CD25
+
 T cells significantly 
increased upon co-incubation with 10μg/ml hBD-2 from 35% in the stimulated control 
to 39.9% in the presence of hBD-2. As it is shown in Figure 3.1C, there is an increase of 
the percentage of CD69
+
CD25
+
 T cells (Q2-UR) on incubation of PBMCs treated with 
hBD-2 at 18hrs (from 35% to 39.9%). Several recent  reports  suggest  that  CD69  may  
exert  a  regulatory  function  in  different  activated  T  cell  subsets. Considered as a 
recent early activation marker, the expression of CD69 has also been found on FoxP3
+
 
Tregs and may act as a marker for recently activated Treg cells which are able to 
recognize locally presented antigens in different tissues (Lieberman et al., 2012). Our 
data indicates that hBD-2 may increase the presence of CD69
+
CD25
+
 T cells at 18hrs 
and this observation may correlate with either the appearance of a greater number of 
CD25
+
CD69
+
 activated T cells or these may represent an increase in the presence of 
newly activated Tregs that express both CD69 and CD25. These data are consistent with 
previously published findings which reveal that mBD-14, an ortholog of hBD-2, is 
capable of inducing the differentiation of Treg cells (Navid et al., 2012). 
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However, interestingly, we found that the percentage of FoxP3
+
 cells in CD4
+
 CD25
high
 
T cells was significantly reduced following 42hrs treatment with 10ug/ml of hBD-2 
(Figure 3.1A, lower left; 3.1B), although there was no significant change in the numbers 
of either CD69
+
CD25
+
or CD69
-
CD25
+
T cells at this time point (Figure 3.1C). Previous 
studies suggested the essential role of FoxP3 in CD4
+
CD25
+
 Treg cells (Hill et al., 2007, 
Sugimoto et al., 2006, Gavin et al., 2007). Additionally, ablation of a conditional FoxP3 
allele in mature Treg cells was found to result in a loss of characteristic gene expression 
and suppressor function as well as the acquisition of effector T cell function (Williams 
and Rudensky, 2007). Thus, the heritable maintenance of a developmentally established 
Treg cell transcriptional and functional program requires continuous expression of 
FoxP3 (Josefowicz et al., 2012). Following 42hrs treatment with 10μg/ml of hBD-2, the 
reduced expression of FoxP3 could indicate a loss of immunosuppressive function of 
these CD4
+
CD25
high
 Tregs.  
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Figure 3.1 hBD-2 treatment increased the percentage of FoxP3
+
 cells in CD4
+
CD25
high
 
T cell population at 18hrs, but down-regulates the percentage of FoxP3
+
 cells in the 
same subsets at 42hrs. A. PBMCs were activated with soluble anti-human CD3 
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(0.005μg/ml) and anti-human CD28 (0.005μg/ml) and co-incubated in the presence or 
absence of 1, 3 and 10μg/ml of hBD-2. After 18hrs and 42hrs incubation, cells were 
stained and analysed by flow cytometry. Data were collected from 3 independent 
experiments (n=3). Statistical analysis was performed using Student t test. *p＜0.05 
versus stimulated control (Stim Co); ** p＜0.01 versus stimulated control (Stim Co).B. 
Histograms showing expression of FoxP3 in CD4
+
CD25
high
 T cells. C. Dot-plots of 
expression of CD25 and CD69 on CD4
+
 T cells. 
 
3.2.2 hBD-2 treatment in the culture of PBMCs induces proliferation of both CD4+ 
and CD8
+
 T cells. 
As discussed previously, we demonstrated that percentage of FoxP3
+
 cells in 
CD4
+
CD25
high
 T cells is significantly reduced following 40hrs incubation with 10ug/ml 
of hBD-2 in these same CD4
+
CD25
high
 T cell population. It has been suggested that the 
decrease of FoxP3 expression in CD4
+
CD25
high
 Tregs may lead to their impaired 
suppressive function. Thus, we would hypothesize that there could be a loss of 
immunosuppressive activity induced by hBD-2 treatment in these cultures following 
42hrs incubation. In order to assess the in vitro immunosuppressive activity of Treg 
cells after treatment with hBD-2, PBMCs were stained with CFSE prior to stimulation 
with αCD3/28 antibodies in order to assess any regulation of proliferation of CD4+ T 
cells following treatment with hBD-2. CFSE is able to bind to intracellular proteins by 
reacting with lysine side-chains and other available amine groups. When cells 
proliferate, CFSE labelled proteins are separated equally into the daughter cells, which 
therefore obtain half of their fluorescence from their parent cells (Hawkins et al., 2007). 
As a result, each generation of proliferation is marked by a halving intensity of CFSE 
fluorescence which can be characterised as several finger-like fluorescent peaks 
displayed in flow cytometry.  
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Data presented in Figure 3.2 and 3.3 suggested that the proliferation of CD4
+
 T cell 
population as well as CD8
+
 T cell population was increased at 72hrs and 96hrs after 
treatment with 10μg/ml hBD-2 (Figure 3.2A and 3.3A). The lower fluorescence 
intensity of CFSE in the treated cells indicates the higher level of proliferation that cells 
were undergoing. With the treatment of hBD-2, the increasing percentage of T cells 
expressing the lower fluorescence intensity can be identified (Figure 3.2B and 3.3B). At 
96hrs there was a shift in percentage of cells that had divided from 53.8% in cells 
stimulated with αCD3/28 alone to 69.6% cells in cell cycle when treated with hBD-2.  
A similar, but less increased finding was observed at 72hrs (Figure 3.2B). Additionally, 
for CD8
+
 T cells, there was an increase in percentage of cells that had proliferated from 
66.5% to 73.5% at 72hrs and an increase from 69% to 81.9% at 96hrs (Figure 3.3B). 
These data suggests that hBD-2 treatment can induce T cell proliferation at 72hrs and 
96hrs.  
 
As discussed previously, the expression of FoxP3 in CD4
+
CD25
high
 Treg cells is 
significantly down-regulated following 42hrs incubation with 10ug/ml of hBD-2 in 
these same CD4
+
CD25
High
 T cells, which may imply defective immunosuppression of 
CD4
+
CD25
high
 Tregs. Tregs are a distinct lineage among newly arising CD4
+
 
thymocytes in expressing CD25. Additionally, it has been previously reported that 
CD4
+
FoxP3
+
 Tregs suppress virus-specific CD8
+
 T cells proliferation and production of 
cytotoxic molecules. The depletion of Treg cells induced CD43
+
 effector CD8
+
 T cells 
to enhanced the levels of the cytotoxic molecules, such as granzyme A and B 
(Zelinskyy et al., 2013). We hypothesise that down-regulation of FoxP3 in Tregs would 
result in an increase of CD8
+
 T cell proliferation due to impaired Treg suppressive 
function.  
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In summary, in vitro proliferation assay using CFSE stained PBMCs revealed that hBD-
2 treatment enhances proliferation of both CD4
+
 and CD8
+
 T cells following 72hrs and 
96hrs culture. These data suggests that any negative control of proliferation provided by 
the FoxP3
+
 Tregs of these CD4
+
 T cells has been partially lost (Figure 3.2 and 3.3).  
 
 
Figure 3.2 hBD-2 treatment induces CD4
+
 T cells proliferation in vitro. A. PBMCs 
were stained with CFSE (5µM) prior to the stimulation with soluble anti-human CD3 
(0.005μg/ml) and anti-human CD28 (0.005μg/ml) and co-incubated in the presence or 
absence of 1, 3 and 10μg/ml hBD-2. Recombinant human IL-2 (0.02μg/ml) was added 
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to promote T cell proliferation. After 72hrs and 96hrs incubation, cells were stained and 
analyzed by flow cytometry. Data were collected from 3 independent experiments (n=3). 
Statistical analysis was performed using Student t test. *p＜0.05 versus stimulated 
control (Stim Co). B. Dot-plots and peak-plots of CFSE fluorescence intensity in CD4
+
 
T cells.  
 
Figure 3.3 hBD-2 treatment induces CD8
+
 T cell proliferation in vitro. A. PBMCs were 
stained with CFSE (5µM) prior to the stimulation with soluble anti-human CD3 
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(0.005μg/ml) and anti-human CD28 (0.005μg/ml) and co-incubated in the presence or 
absence of 1, 3 and 10μg/ml hBD-2. Recombinant human IL-2 (0.02μg/ml) was added 
to promote T cell proliferation. After 72hrs and 96hrs incubation, cells were stained and 
analyzed by flow cytometry. Data were collected from 3 independent experiments 
(n=3).Statistical analysis was performed using Student t test. *p＜ 0.05 versus 
stimulated control (Stim Co). B. Dot-plots and peak-plots of CFSE fluorescence 
intensity in CD8
+
 T cells.  
 
3.2.3 Co-culture with hBD-2 reduces induction of T cell apoptosis at 18hrs but 
enhances levels of apoptosis at 42hrs. 
In order to analyse the level of apoptosis induced in CD4
+
 T cells by treatment with 
hBD-2, PBMCs were stained with Annexin-V to characterise any apoptotic cells 
following αCD3/28 co-stimulation in the presence and absence of hBD-2. Annexin-V is 
a phospholipid-binding protein that is capable of binding with phosphatidylserine (PS). 
In normal cells, PS is located in the inner leaflet of the cytoplasm membrane. However, 
upon initiation of apoptosis, PS loses its asymmetric distribution across the cell 
membrane and is trans-located to the cell surface. This then allows Annexin V, labelled 
with fluorescence, to bind to PS on the cell surface of the membrane indicating 
apoptosis occurring in cells.  
 
Results presented in Figure 3.4 indicated that, at 18hrs, there was a small but significant 
decrease in Annexin-V expression following treatment with hBD-2 which suggested 
that the apoptosis of CD4
+
 T cells was partially suppressed in the presence of 10μg/ml 
hBD-2 (Figure 3.4, left hand panel). However, at 42hrs, there was a significant increase 
observed in Annexin-V staining which suggested that the apoptosis of CD4
+
 T cells was 
increased in the presence of 10μg/ml hBD-2 relative to the control (Figure 3.4, right 
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hand panel). These data suggest that hBD-2 may play a role in inhibiting CD4
+
 T cells 
apoptosis at 18hrs and induce CD4
+
 T cells apoptosis at 42hrs. According to a recently 
published paper, hBD-3 was found to be capable of suppressing neutrophil apoptosis by 
up-regulating in expression of Bcl-x(L) and suppressing the activation of caspase-3 
(Nagaoka et al., 2010). However no role has been documented to date for a pro-
apoptotic effect of hBD-2 on immune cells making these findings particularly 
interesting 
 
 
Figure 3.4 Annexin-V staining on CD4
+
 T cells at 18hrs and 42hrs. PBMCs were 
stimulated with soluble anti-human CD3 (0.005μg/ml) and anti-human CD28 
(0.005μg/ml) and treated with 1, 3 and 10μg/ml hBD-2. After staining by cell surface 
markers, cell suspension was washed by Annexin-V binding buffer. FITC-conjugated 
Annexin-V was added in cell suspension with a recommended concentration by the 
manufacturer‟s instructions. Data were collected from 3 independent experiments (n=3). 
Statistical analysis was performed using Student t test. *p<0.05 
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3.2.4 hBD-2 and hBD-3 induce the appearance of a CD69+CD25-CCR6+ subset at 
18hrs, but at 42hrs, hBD-2 and hBD-3 induced the appearance of a 
CD69
+
CD25
+
CCR6
-
 subset and a CD69
-
CD25
+
CCR6
-
 subset. 
CCR6 is a CC chemokine receptor which is an important receptor that is involved in 
regulating several many aspects of mucosal immunity (Ito et al., 2011). It has been 
reported that not only the chemokine CCL20, but also the non-chemokine peptides 
hBD-2 and hBD-3 can function as ligands for human CCR6 (Yang, 1999, Schutyser et 
al., 2003). In order to investigate whether expression of CCR6 was required for hBD-2 
induced CD4
+
 T cell activation, this CCR6
+
 population was looked at specifically. 
Firstly, we analysed the percentage of CCR6
+
CD4
+
 T cells in the PBMCs culture. We 
found that there was no significant change in the numbers of percentage of CD4
+
CCR6
+
 
T cell population following 18hrs culture or 42hrs culture (Figure 3.5A). Then, 
CD4
+
CCR6
+
 T cells were gated and analysed for expression of the activation markers 
CD69 and CD25. As shown in Figure 3.5B, gates were set up to select CD4
+
CCR6
-
 
(Gate: R7) and CD4
+
CCR6
+
 (Gate: R6) cells. When compared with the CD4
+
CCR6
-
 
subset, CD4
+
CCR6
+
 cells aggregated collected in the CD25
+
 section quartiles at both 
18hrs and 42hrs. At 18hrs, 53.2% of these cells were CD69
+
CD25
+
 phenotype, 
increased from 22.0% in CCR6
-
 subset. There were also 29.0% of the CCR6
+
 cells were 
CD69
-
CD25
+
 cells and this had in CCR6
+
 cells increased from 11.7% when compared 
to CCR6
-
 cells. However, for in respect of the CD69
+
CD25
-
 subset, the percentage 
decreased from 19.3% to 5.8% in CCR6
+
 cells. The statistical analysis revealed that 
there was a significant increase of CD69
+
CD25
+
 and CD69
-
CD25
+
 cells in the 
CD4
+
CCR6
+
 T cells, and significant decrease of CD69
+
CD25
-
 phenotypes in 
CD4
+
CCR6
+
 T cells (Figure 5C). Interestingly, these data suggested that CCR6
+
 T cells 
may respond more quickly to αCD3/28 activation as there are more cells expressing the 
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phenotype that is characteristic of the later stages of activation which is CD69
+
CD25
+
 
and CD69
-
CD25
+
.  
 
Figure 3.5 CCR6 staining on CD4
+
 T cells in human PBMCs culture. A. the percentage 
of CD4
+
CCR6
+
 T cells in the PBMCs culture. B. dot plots showing the gate strategy to 
distinct CCR6
-
 and CCR6
+
 subsets in the samples and analysing the expression of CD69 
and CD25 in these subsets. C. statistical analysis comparing the percentage of different 
CD4
+
 T cells phenotypes regarding to the activation markers between CCR6
-
 and 
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CCR6
+
 subsets. Data were collected from 3 independent experiments (n=3). Statistical 
analysis was performed using Student t test.  *p<0.05 
 
Having established the use of gates to analyse the activation status of CCR6
+
 and 
CCR6
-
CD4
+
 T cells, we went on to analyse the effect of co-culture of these cells with 
hBD-2 and hBD-3. Next, we found that the population of CCR6
+
CD69
+
CD25
-
 were 
significantly increased by 50% in the presence of hBD-3 and to a lesser extent of hBD2 
at 18hrs (Figure 3.6), whereas no such effect was observed in the case of CCR6
-
CD69
+
CD25
-
 subset cells did not show any significance. These data suggested that 
hBD-2 or hBD-3 induced more CCR6
+
 unstimulated T cells express CD69 at their 
earlier stage of activation. This induction may lead to the up-regulation of CCR6
+
 T cell 
activation. Moreover, as the percentage increase of CCR6
+
CD69
+
CD25
-
 was more 
dramatic increased greater in the presence of hBD-3 than when compared to hBD-2, it 
would appear that this CD4
+
CCR6
+
 T cell population response more quickly at the early 
stage of activation, possibly reflecting a difference of affinity in binding to CCR6 
between hBD-2 and hBD-3.  
 
Figure 3.6 hBD-2 and hBD-3 induced increase of CD69
+
CD25
-
CCR6
+
 T cell subset at 
18hrs. Data were collected from 3 independent experiments (n=3). *p<0.05 
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At By 42hrs this CCR6 dependent effect was lost, we observed a very small (1.1 fold) 
but significant increase of both the CCR6
+
CD69
+
CD25
+
 subset and the CCR6
-
 
CD69
+
CD25
+
 in the presence of hBD-2. However, this very small increase mediated by 
the presence of hBD-2 may have no physiological meaning as it is so small (Figure 3.7 
left). However, in the co-incubation with hBD-3, there was a very small but significant 
increase of the same subset only in CCR6
-
 but not in CCR6
+
 CD4
+
 T cells (Figure 3.7 
right).  
 
Finally, there was a significant increase observed in the presence of both hBD2 and 
hBD3 at 42hrs in CCR6
-
CD69
-
CD25
+
 T cells. This effect was not observed on the 
corresponding CCR6
+
 T cell population. The presence of CCR6
-
 cells, but not CCR6
+
 
cells, in the CD69
-
CD25
+
 subset increased when treated with hBD-2 or hBD-3 at 42hrs 
(Figure 3.8). Taken together, these data suggest that at 42hrs it is not CCR6
+
 cells but 
CCR6
-
 cells that have responded to hBD-2 and hBD-3 or, alternatively,  that this is an 
affect that has occurred as a consequence of an earlier event in activation. These data 
suggest that there may be alternative receptors or pathways to CCR6 that may be ligated 
by hBD2 and hBD3 in order to induce CD4
+
 T cell activation by hBD-2 and hBD-3. 
 
 
38 
 
 
Figure 3.7 hBD-2 induced both CCR6
-
 and CCR6
+
CD69
+
CD25
+
 cell subset at 42hrs, 
whereas hBD-3 induced increase of CCR6
-
 but not CCR6
+
 T cells in CD69
+
CD25
+
 cell 
subset at 42hrs. Data were collected from 3 independent experiments (n=3). *p<0.05 
 
 
Figure 3.8. hBD-2 and hBD-3 induced increase of CCR6
-
 but not CCR6
+
 T cells in 
CD69
-
CD25
+
 cell subset at 42hrs. Data were collected from 3 independent experiments 
(n=3). *p<0.05, **p<0.01 
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3.3 Discussion 
As it has been reported that hBD-2 may act as a modulator of T cell cytokine production 
(Kanda et al., 2011), and also is able to suppress the immune response by inducing the 
differentiation of Treg phenotype (Navid et al., 2012), it was our original aim to further 
investigate the immunomodulatory effects of hBD-2 on human peripheral T cells. In 
this chapter, we suggest that human PBMCs treated with hBD-2 causes an up-regulation 
in numbers of CD4
+
CD25
high
 T cells at 18hrs post-activation stimulus and these 
numbers remain elevated following 40hrs in culture. Characterisation of FoxP3 staining 
also reveals an enhanced expression of this transcription factor in the CD4
+
CD25
high
 T 
cell subset at 18hrs. 
 
However, we found that the percentage of FoxP3
+
 T cells is significantly decreased 
following 42hrs treatment with hBD-2 in these same CD4
+
CD25
high
 T cell population in 
vitro. It has been demonstrated that FoxP3 plays a key transcriptional factor to the 
development and function of Treg cells (Josefowicz et al., 2012, Bilate and Lafaille, 
2012). These results could indicate a loss of function of Treg cells upon co-culture with 
hBD-2. Indeed, it has been previously shown that an experimentally induced reduction 
in the expression of FoxP3resulted in impaired suppressive function of Treg cells (Wan 
and Flavell, 2007). Additionally, it is of note that it has been shown that in developing 
Treg cells, CD28 co-stimulation induces FoxP3 expression, which most likely occurs 
through the activation of NF-κB signalling pathway and binding of c-Rel to non-coding 
sequence elements in the Foxp3 gene (Tai et al., 2013).  
 
However, as we had observed that there was an apparent up-regulation in FoxP3
+
 Tregs 
by 18hrs, but an apparent loss of these cells as they appear to lose FoxP3 expression at 
42hrs. Therefore, we hypothesised that this finding might result in a loss of Treg 
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suppressive activity and that this effect would promote the proliferation of effector T 
cells in our cell cultures. Consistent with this idea we found that, using analysis of 
CFSE stained PBMCs, the proliferation of CD4
+
 T cells in vitro is enhanced by hBD-2 
treatment after both 72hrs and 96hrs.This result suggests the negative control of 
proliferation of these CD4
+
 effector T cells by Tregs has been partially lost.  
 
Several previous studies have indicated hBD-2 has direct effects on T cells. Boniotto et 
al. analysed the effects of both hBD-2 and hBD-3 on the induction of secretion of 
cytokines and chemokines by PBMCs using a protein-array, in order to describe a role 
for human β-defensins in the induction of pro-inflammatory response in these cells 
(Boniotto et al., 2006). Their investigation suggest the expression of IL-6, IL-8 and IL-
10 is enhanced by co-culture of with hBD-2 and human PBMCs. Further studies by 
Kanda et al. (2011) revealed the effects of hBD-2 on the purified human CD3
+
 T cell 
population. They illustrated that the effects of hBD-2 on T cell were to enhance 
secretion of TNF-α, IFN-γ,IL-1β, IL-6, IL-10 and IL-22. These data suggest that hBD-2 
is able to manifest feedback to T cells in order to sustain maintain or halt their own 
cytokine production. hBD-2 was also shown to induce an increase in secretion of the 
immunoregulatory cytokine, IL-10, which can itself induce the development of Treg 
cells. On the other hand, hBD-2 also induced the production of pro-inflammatory 
cytokines, such as IFN-γ, TNF-α, IL-1β, IL-6 and IL-22 expression by human CD3+ T 
cells (Kanda et al., 2011). TNF-α, IL-1β and IL-6 can themselves also induce the 
production of IL-12 and IL-12 inhibits Treg cell conversion and expansion. It has also 
been shown that IL-6 together with TGF-β abrogates Treg generation and drives naive 
T cells to develop into Th17 cells (Kimura and Kishimoto, 2010). Th17 cells may then 
produce IL-17, IL-21 and IL-22 which are able to induce inflammation in tissues (Korn 
et al., 2009). Collectively, these data suggest that hBD-2 may indirectly and directly 
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affect the development and function of both Treg and Th17 cells through the regulation 
of cytokine. Thus this complex regulation of the immune response by the defensins 
involves the secretion of a wide range of cytokines with apparently opposing effects and 
as such a homeostatic control of the immune response may be maintained. 
 
The role of CCR6 in mediating these reported hBD2 and hBD3 effects remains 
controversial (Lee et al., 2015). Some researchers have reported that CCR6 functions as 
a receptor for hBDs (Yang, 1999, Schutyser et al., 2003), whilst other report that its 
expression is not necessary to mediate hBD-2 and hBD-3 effects (Soruri et al., 2007). 
Others suggest that it is a question of affinity. It is suggested that hBD-2 was less 
effective than CCL20 in interacting with CCR6 (Yang, 1999). However, although the 
affinity of hBD-2 and for CCR6 is lower than CCL20, hBD-2 was shown to be capable 
of inducing the arrest of human Th17 cells on arrest to inflamed epithelial cells in vitro 
via CCR6 (Ghannam et al., 2011). Interestingly, in contrast to CCL20, co-incubation 
with hBD-2 did not lead to Ca
2+
 mobilization in CCR6-expressing Th17 cells 
(Ghannam et al., 2011). Because Ca
2+
 mobilization plays an essential role in T cell 
activation (Shi et al., 2013, Joseph et al., 2014), these findings suggest that there may 
be other receptors capable of responding to hBD-2 during the process of T cell 
activation. Kanda et al. (2011) demonstrated that hBD-2 may also regulate the 
activation and cytokine production in CD3
+
 T cells via PTX-sensitive G-protein coupled 
receptors, rather than CCR2, CCR6, or TLR4. In our study, we demonstrated that hBD-
2 and hBD-3 may influence the events of early activation in a CCR6 dependent fashion 
but then influence the later stages of activation in a CCR6 independent fashion. These 
data may suggest the possibility that alternative receptors could be ligated by hBDs in 
order to induce CD4
+
 T cell activation in vitro, and further study is required in order to 
identify which receptors are involved in this process. 
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3.4 Conclusion 
In this chapter, our results reveal that hBD-2 may play both a positive and negative role 
in the development of Treg cells by regulating the expression of FoxP3. Initially, the 
positive regulatory effect is found by an up-regulation in numbers of CD4
+
CD25
+
 Tregs 
that also express elevated levels of FoxP3. The later negative regulatory effect is 
identified by a loss of FoxP3
+
 cells in these CD4
+
CD25
+
 Treg population, leading to a 
limited ability of these Treg cells to slow down the proliferation of CD4
+
 effector T 
cells in the presence of hBD-2. In addition, we observed an increase of early activated 
CD69
+
CD25
-
CCR6
+
 CD4
+
 T cells population but not CD69
+
CD25
-
CCR6
-
 CD4
+
 T cell 
in the presence of hBD-2 or hBD-3 at 18hrs. This suggested that hBD-2 or hBD-3 may 
act via CCR6 thereby inducing the appearance of more CCR6-expressing unstimulated 
T cells which also express CD69 at their earlier stage of activation. However, by 42hrs, 
only the later activated T cells, CD69
+
CD25
+
CCR6
-
 and CD69
-
CD25
+
CCR6
-
 subsets 
appeared to respond to hBD-2 and hBD-3, whereas CCR6-expressing subsets did not 
show any significant changes. This data may suggest that there are alternative receptors 
or pathways to induce CD4
+
 T cell activation by hBD-2 and hBD-3 at the later stages in 
activation.  
 
These data suggest a role for hBD-2 in regulating the adaptive immune response, 
however, as these investigations were carried out on mixed PBMCs we could not rule 
out the possibility that another cell type other than the CD4
+
 T cell was responsible for 
mediating the observed effects of hBD-2 and hBD-3. In Chapter 4, we will focus on 
analysing purified human CD4
+
 T cells in order to investigate whether these findings 
are intrinsic to CD4
+
 T cells. 
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Chapter 4: Effect of hBD-2 and hBD-3 on purified human 
CD4
+
 T cells 
4.1 Introduction 
CD4
+
 T cells and CD8
+
 T cells comprise the two major lineages of peripheral T 
lymphocytes. Both CD4 and CD8 are co-receptors expressed on peripheral T cells that 
play essential roles in T cell development. Distinct from MHC I - restricted CD8 
cytotoxic T cells, CD4 T cells are MHC II - restricted T helper cells. CD8
+
 T cells 
function as effector cells capable of inducing cell death of virus infected cells or cancer 
cells, whereas CD4
+
 T cells can differentiate to become one of several different T helper 
cell phenotypes which play different and important roles in the activation of other 
immune cells and may therefore regulate the immune response (Kleinewietfeld and 
Hafler, 2013, Korn et al., 2009, Vahedi et al., 2013). However, additional to their ability 
to act as helper cells, they can also become “troublemakers” leading to the development 
of autoimmune diseases and allergies (Hirahara et al., 2013).  
 
Upon recognition of antigen, CD4
+
naïve T cells may be polarised to become Th1, Th2, 
Th17, Tfh and regulatory T cell (Treg) With the exception of Tregs, all other T helper 
subsets play a role in combating infection. In the case of CD4
+
 Tregs, these cells are 
described mainly as being a distinct lineage of cells which form an essential component 
of the immune response and are responsible for maintaining the homeostasis of the 
immune system (Josefowicz et al., 2012, Kleinewietfeld and Hafler, 2013, Bilate and 
Lafaille, 2012). Treg cells function as inhibitors of activation and proliferation of other 
effector T cells including CD4
+
 T effectors, CD8
+
 T cells, NK cells, B cells and APCs 
(Kleinewietfeld and Hafler, 2013, Josefowicz et al., 2012). Tregs can be characterized 
not only by expression of CD4 on their cell surface but also by their high expression of 
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CD25 (also known as IL-2Rα) and by the expression of the transcriptional factor FoxP3 
(Kleinewietfeld and Hafler, 2013). FoxP3 has been considered as „a lineage-
specification factor‟ for Treg cell differentiation and function (Ramsdell and Ziegler, 
2014). Also, the maintenance of suppressive function by Treg cells requires continuous 
expression of FoxP3 (Williams and Rudensky, 2007). In humans, Treg cells were found 
to also have low expression of IL-7R (CD127) (Liu et al., 2006, Hartigan-O'Connor et 
al., 2007).   
 
CD4
+
 T cell activation and proliferation is regulated by Treg cells. The mechanism of 
Treg-mediated suppressive function is mainly dependent on cell-to-cell contact 
mechanisms, such as CTLA-4-dependent blockade of co-stimulation, the release of 
suppressive cytokines (e.g. TGF-β, IL-10 or IL-35), or the production of suppressive 
metabolites (e.g. adenosine) (Kleinewietfeld and Hafler, 2013, Tai et al., 2012, Shevach, 
2009). FoxP3 plays a key role in Treg suppressive function (Rowe et al., 2012, 
Josefowicz et al., 2012). Binding of FoxP3 cannot only induce CTLA-4 expression and 
the production of cytokines which mediate immune-suppression (Hossain et al., 2013), 
but also can interact with RORγt protein to inhibit Th17 differentiation (Chen et al., 
2011).  
 
More recently, a novel mechanism was reported whereby auto-Treg cells release CD73-
expressing exosomes to suppress CD4
+
CD25
−
 T-cell proliferation following TCR 
activation (Smyth et al., 2013). Tregs can mediate their suppressive function via transfer 
miRNA-containing exosomes to Th1 cells in order to inhibit proliferation and cytokine 
production by effecter T cells (Okoye et al., 2014).  
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In Chapter 3, we reported that co-culture of mixed PBMCs with hBD-2 induced human 
CD4
+
 T cell activation and proliferation in vitro. In addition, we found that hBD-2 
treatment may trigger both a positive and negative effect in the development of human 
Tregs by regulating the expression of FoxP3 at different time points. Following 18hrs 
co-culture, hBD-2 induced an up-regulation in the expression of FoxP3 in 
CD4
+
CD25
high
 Tregs. By 42hrs, however, hBD-2 treatment caused a down-regulation of 
FoxP3 expression in these CD4
+
CD25
high
 Tregs which may cause these Tregs to lose 
their ability to control the proliferation of CD4
+
 effector T cells, thus leading to the up-
regulated levels of proliferation. It is not clear whether the observations described in 
Chapter 3 are due to a CD4
+
 T cell intrinsic effect or to the presence of another cell 
contained within the PBMC population. Therefore, we will focus on purified human 
CD4
+
 T cells in this chapter and investigate whether the effect of hBD treatment on 
CD4
+
 T cells is, in fact, intrinsic to CD4
+
 T cells themselves. 
 
4.2 Results 
4.2.1 hBD-2 treatment in purified CD4+ T cells induces an increase in the percentage 
of FoxP3
+
 cells in human CD4
+
CD25
high
 T cells by 18hrs, but suppresses the 
Foxp3
+
 cells by 42hrs. 
In order to prepare a culture of purified T helper cells, human CD4
+
 T cells were 
isolated using magnetic bead enrichment kit and then stimulated in culture using plate 
bound anti-CD3 (0.1µg/ml) and soluble anti-CD28 (2µg/ml) antibodies. Cell cultures 
were observed using an inverted microscope (Figure 4.1 and Figure 4.2). Cell clusters 
indicate the degree of activation as T cell activation is accompanied by the up-
regulation of expression of adhesion molecules on the T cell surface which allows T 
cells to stick together forming clumps. Compared to the stimulated control, the diameter 
of T cell clusters co-incubated with hBD-2 and 3 increased by 18hrs and 42hrs. This 
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data suggests that there could be a greater number of CD4
+
 T cells activated in the 
presence of hBD-2 and hBD-3 when compared to the stimulated only control. 
 
Following this observation using the microscope, CD4
+
 T cells were isolated from the 
cultures and stained with fluorescence conjugated antibodies and analysed using flow 
cytometry. Following co-incubation of CD4
+
 T cells with hBD-2 and an activation 
stimulus for 18hrs, there was an increased induction of CD69
+
CD25
+
 T cells from 11.8 
to 20.7% in the presence of 10ug/ml hBD-2 (Figure 4.3 A, upper panel). This finding is 
consistent with the data obtained using whole PBMCs (Chapter 3, Figure 3.1). Although 
the percentage of CD69
-
CD25
+
 subset remains at 10.0% in the experiment presented in 
Figure 4.3A, statistical analysis showed that there was a small but significant increase 
by 1.2 fold of the CD69
-
CD25
+
 population (Figure 4.3 B). In addition to this effect 
observed with hBD-2, co-culture with hBD-3 increased the presence of CD69
+
CD25
+
 
subset from 11.8% to 22.3%, and induced an increase in the presence of CD69
-
CD25
+
 
subset from 10.0% to 12.6%. Statistical analysis showed that co-culture with hBD-3 
significantly induced the percentage of the CD69
-
CD25
+
 subset at 18hrs by a fold 
change which is greater than the effect observed with hBD-2. 
 
Moreover, following co-incubation of CD4
+
 T cells with hBD-2 for 42hrs, the 
percentage representation of the CD69
+
CD25
+
 T cell subset significantly increased from 
10.3% to 14.05%, and the percentage representation of the CD69
-
CD25
+
 T cell subset 
significantly increased from 21.2% to 27.5% (Figure 4.3 A, lower panel). Interestingly, 
we found that co-incubation of T cells with hBD-3 had a more dramatic effect on T cell 
differentiation than co-culture with hBD-2. In the case of hBD-3, there was an increase 
in the presence of CD69
+
CD25
+
from 10.3% to 26.7% and an increase of CD69
-
CD25
+
 
subset from 21.2% to 33.4% (Figure 4.3 A, lower panel). It seems that after the phase of 
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early activation, the expression of CD69 was down-regulated while the expression of 
CD25 was up-regulated. CD25
-
CD69
+
 T cells developed into CD25
+
CD69
+
 T cells and 
then into the CD25
+
CD69
-
 phenotype. Taken together, these results suggested an up-
regulation in CD4
+
 T cell activation by both hBD-2 and hBD-3. 
 
 
Figure 4.1 Morphology of purified CD4
+
 T cell culture with or without the treatment of 
hBD-2 and 3 at 18hrs. Purified CD4
+
 T cells were stimulated using plate bound anti-
human CD3 (0.1µg/ml) and soluble anti-human CD28 (2µg/ml) in the presence or 
absence of hBD-2 (10µg/ml) or hBD-3 (10µg/ml). The unstimulated control sample was 
purified CD4
+
 T cells cultured without antibody stimulation. After 18hrs incubation, 
plates were taken out of incubator and placed under microscope to observe and 
photograph the cell layout and clustering. 
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Figure 4.2 Morphology of purified CD4
+
 T cell culture with or without the treatment of 
hBD-2 and 3 at 42hrs. Purified CD4
+
 T cells were stimulated using plate bound anti-
human CD3 (0.1µg/ml) and soluble anti-human CD28 (2µg/ml) in the presence or 
absence of hBD-2 (10µg/ml) or hBD-3 (10µg/ml). The unstimulated control sample was 
purified CD4
+
 T cells cultured without antibody stimulation. After 42hrs incubation, 
plates were taken out of incubator and placed under microscope to observe and 
photograph the cell layout and clustering. 
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Figure 4.3 hBD-2 and 3 induce CD69 and CD25 expression on human CD4
+
 T cells. A. 
Dot-plots for CD69 and CD25 expression on human CD4
+
 T cells from one experiment; 
B. Statistical analysis of CD69
+
CD25
+
 and CD69
-
CD25
+
 subsets in the presence of 
hBD-2 and 3 at 18hrs and 42hrs. Data were collected from 5 independent experiments 
(n=5). *p<0.05 
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4.2.2 Proliferation of CD4+ T cells was increased following treatment with hBD-2 and 
3 for 72hrs and 96hrs. 
In order to investigate the effect of co-culture of T cells with hBD-2 and hBD-3 on T 
cell proliferation, purified human CD4
+
 T cells were stained with CFSE prior to 
stimulation with αCD3/28 antibodies. Data presented in Figure 4.4 suggested that the 
proliferation of CD4
+
 T cells was increased from 38.4% in the stimulated control to 
48.7% in the presence of hBD-2 and the percentage increased to 52.8% in the presence 
of hBD-3. These data suggest that co-incubation of T cells with an activation stimulus 
as well as hBD-2 or hBD-3 induces significantly increased T cell proliferation at 96hrs 
(Figure 4.5A). This finding could be considered to be consistent with the observed 
increase in activation of T cells in the presence of hBD-2 and hBD-3. As proliferation 
of T cells is mediated, in part, by interleukin-2 (IL-2), the IL-2 production in the 
supernatant at 18 and 42hrs was detected using ELISA. The data shown in Figure 4.5B 
demonstrates that co-culture with hBD-2 and hBD-3 induces a significant up-regulation 
of IL-2 production by CD4
+
 T cells by 18hrs. Although the overall level of IL-2 went 
down by 42hrs, there is still a trend towards an increase in IL-2 production in the 
presence of hBD-3 (Figure 4.5). It is possible that at this time point IL-2 may have been 
absorbed out of the system by the increased presence of the IL-2Rα (CD25) expressed 
on the surface of the activated T cells thereby accounting for the drop in IL-2 levels 
observed in the cultures. These data suggest that co-culture with hBD-2 or hBD-3 
induces CD4
+
 T cells to produce more IL-2 which in turn is able to promote CD4
+
 T 
cell proliferation in vitro. 
 
This data is seemingly inconsistent when considered alongside the finding that the 
presence of CD69
-
CD25
+
 putative Tregs is increased in these cultures. These findings 
could imply loss of immunosuppressive function of the Tregs following treatment with 
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hBD-2 or hBD-3 as expression of FoxP3 is a requirement for the suppressive function 
of Treg cells.  
 
Furthermore, CD25 is a subunit of the high-affinity IL-2 receptor (IL-2R). It is therefore 
possible that as Tregs are described to mop up excess IL-2 via the binding of CD25 to 
IL-2 in the local environment and as IL-2 is crucial for Treg cell expansion and 
maintenance, decreased level of IL-2 in the local environment may lead to a reduction 
in T cell proliferation  (Boyman and Sprent, 2012, Zhang et al., 2013). Interestingly, 
high level of IL-2Rα expression is required for Treg cells homeostasis and this function 
is considered as FoxP3-dependent (Josefowicz et al., 2012). Dysregulated Tregs may no 
longer be capable of their suppressive function thus allowing a higher level of 
proliferation of the Teffs cells (Tai et al., 2013).  
 
Figure 4.4 hBD-2 and hBD-3 treatment induces the proliferation of purified CD4
+
 T 
cells in vitro. Purified CD4
+
 T cells were stained with CFSE (5µM) prior to activation. 
CFSE labelled CD4
+
 T cells were activated with plate bound anti-human CD3 
(0.1μg/ml) and soluble anti-human CD28 (2μg/ml) and treated with 10μg/ml hBD-2 or 
hBD-3. After 96hrs incubation, cells were stained and analysed by flow cytometry. 
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Figure 4.5 hBD-2 and hBD-3 treatment significantly enhanced the proliferation of 
CD4
+
 T cells following 96hrs culture and increased the protein level of IL-2 in the 
supernatant of CD4
+
 T cell culture in vitro. A. the statistical analysis of the fold change 
of proliferated CD4
+
T cells; B. IL-2 concentration was detected in the supernatants 
using ELISA. The factor of treatment was analysed using One-way ANOVA and the 
factor of time was analysed using Two-way ANOVA. Data were collected from 3 
independent experiments (n=3). * p<0.05; ** p<0.01 
 
4.2.3 FoxP3 and CTLA-4 expression of CD4+ T cells co-cultured with hBD-2 and 3. 
In order to investigate the expression of FoxP3 in CD127
-
CD25
+
 Treg cells, we used 
intracellular staining techniques on cell isolated from the purified CD4
+
 T cell cultures. 
Interestingly, we demonstrated that the percentage of FoxP3
+
 cells within the CD127
-
CD25
+
 Treg population significantly increased from 28.0% to 34.6% in the presence of 
hBD-2. Also, we observed that following co-culture with hBD-3, the percentage of 
FoxP3
+
 cells within the CD127
-
CD25
+
 Treg population significantly increased even 
more dramatically from 28.0% to 44.1% (Figure 4.6 and 4.8). These findings suggested 
that treatment with hBD-2 and hBD-3 can induce more CD4
+
 cells to differentiate into 
CD127
-
CD25
+
FoxP3
+
 Treg phenotype when CD4
+
 T cells are activated by αCD3/28 in 
vitro. We also assessed CTLA4 expression in the CD127
-
CD25
+
 Treg subset. However, 
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we could not find any cell surface expression of CTLA4 on the Treg subsets suggesting 
that if present, the expression of CTLA4 was below the levels of detection in our assay 
(Figure 4.7). We then analysed intracellular CTLA4 expression and found that treatment 
with hBD-2 significantly induced the appearance of a population of FoxP3
+
CTLA4
+
 
subset within the CD127
-
CD25
+
 population of Treg cells. In comparison, treatment with 
hBD-3 induced a significant increase in the FoxP3
+
CTLA4
-
 subset (Figure 4.7 and 4.8). 
These results indicated that the treatment with hBD-2 may promote both FoxP3 and 
intracellular CTLA4 expression in CD127
-
CD25
+
 Tregs by 18hrs, whereas hBD-3 
treatment only induced FoxP3 expression in CD127
-
CD25
+
 Tregs by 18hrs. These 
findings are consistent with our observation using PBMCs (Chapter 3) as well as the 
previously published findings which reveal mBD-14, a homologue of hBD-2, is capable 
of inducing the development of Tregs in CD4
+
CD25
-
 T cells in mice(Navid et al., 2012). 
However, by 42hrs, we found the presence of the FoxP3
+
 population of Tregs was 
significantly decreased after the treatment with  hBD-2 or hBD-3, even though the 
overall percentage of FoxP3
+
 cells was raised in all samples from 18 to 42 hrs in culture 
(Figure 4.6 B and 4.9). These data suggest that CD127
-
CD25
+
 Treg cells may lose their 
expression of FoxP3 following the treatment with hBD-2 or hBD-3 for 42hrs and this 
may lead to the defective function of these CD127
-
CD25
+
 Treg cells. We then went on 
to investigate the expression of CTLA4 in CD127
-
CD25
+
 Treg cells. Surprisingly, we 
found that there was a significant up-regulation of FoxP3
+
CTLA4
+
 cells in the presence 
of hBD-2 or hBD-3, although there was a significant decrease in the presence of 
FoxP3
+
CTLA4
-
 cells with the co-culture of hBD-2 or hBD-3 (Figure 4.9).  
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Figure 4.6 Percentages of FoxP3
+
 subsets in Treg and Teff cells at 18hrs. Purified 
human CD4
+
 T cells were stimulated using αCD3/28 antibodies and co-cultured with 
hBD-2 or 3 for 18hrs. Treg population was characterized as CD127
-
CD25
+
 subset. Teff 
population which has been activated was characterized as CD127
+
CD25
+
 subset. Gating 
on the Treg subset and Teff subset, the percentages of FoxP3
+
 cells were measured 
respectively. A. Cells that were cultured for 18hrs; B. Cells that were cultured for 42hrs. 
Data were collected from 5 independent experiments (n=5). 
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Figure 4.7 Intracellular staining for FoxP3 and CTLA-4 expression in CD127
-
CD25
+
 
Treg cells at 18hrs and 42hrs.Purified human CD4
+
 T cells were stimulated using 
αCD3/28 antibodies and co-cultured with hBD-2 or 3 (10µg/ml). Cells were gated on 
CD4
+
CD127
-
CD25
+
 Treg subset. The left panel shows the cell surface staining of 
CTLA-4 and the rest of the dot-plots show the staining for intracellular CTLA-4. Data 
were collected from 3 independent experiments (n=3). 
 
56 
 
 
Figure 4.8 Statistical analysis of FoxP3 and CTLA-4 expression at 18hrs. 
FoxP3
+
CTLA4
+
 and FoxP3
+
CTLA4
-
 T cell subsets were gated on CD127
-
CD25
+
 T cells. 
Fold changes were calculated relative to the percentage of Stim Co. Data were collected 
from 3 independent experiments (n=3). *p<0.05 
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Figure 4.9 Statistical analysis of FoxP3 and CTLA-4 expression at 42hrs. 
FoxP3
+
CTLA4
+
 and FoxP3
+
CTLA4
-
 T cell subsets were gated on CD127
-
CD25
+
 T cells. 
Fold changes were calculated relative to the percentage of Stim Co. Data were collected 
from 3 independent experiments (n=3). *p<0.05 
 
4.3 Discussion 
Recent studies have shown that hBD-2 is capable of inducing an increase in the 
phosphorylation of JNK, ERK, and Akt, following activation with αCD3/28 suggesting 
that treatment of T cells with hBD-2 may enhance the degree of  activation of CD3
+
 T 
cells in vitro (Kanda et al., 2011). In addition to the effect observed with hBD-2, 
treatment with hBD-3 was also reported to stimulate STAT1 tyrosine phosphorylation 
in CD3
+
CD45RO
+
 T cells but was unable to induce MAPK activation  indicating, 
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possibly, that hBD-2 and hBD-3 exert their effects differently on the induction of T cell 
activation (Meisch et al., 2013). Thus the distinct roles of hBD-2 and 3 in human CD4
+
 
T cell activation remains to be characterised. In Chapter 3, we demonstrated that 
treatment with hBD-2 and 3 up-regulate the numbers of CD4
+
CD69
+
CD25
+
 T cells 
following 18hrs in cultures of human PBMCs. To investigate whether this effect is a 
CD4
+
 T cell intrinsic effect, we assessed the role of hBD-2 and 3 in purified human 
CD4
+
 T cell activation and proliferation.  
 
The data presented in this chapter demonstrated that following co-stimulation of T cells 
with αCD3/28 and hBD-2 or hBD-3 significantly up-regulated the presence of 
CD69
+
CD25
+
 T cells at both 18 and 42hrs in purified CD4
+
 T cell culture. We 
additionally demonstrated that treatment with hBD-2 significantly increased the 
presence of the CD69-CD25
+
 T cells subset at both time points, whereas treatment with 
hBD-3 only induced a significant increase in the presence of CD69
-
CD25
+
 T cell by 
18hrs post-activation stimulus. These data may reflect the different potencies between 
hBD-2 and 3 and indicate that hBD-2 may push CD4
+
 T cell activation more quickly 
through the CD69
+
CD25
+
 stage, or hBD-3 may inhibit activation of CD4
+
 T cells in this 
double positive phase. These data suggest that the presence of both hBD-2 and 3 may 
augment human CD4
+
 T cell activation following αCD3/28 in vitro. Consistent with this 
finding, we also showed that CD4
+
 T cell proliferation also enhanced in the presence of 
hBD-2 or 3 by 96hrs. These results reveal the capability of hBD-2 and 3 in possibly 
accelerating and enhancing human CD4
+
 T cell activation and proliferation.  
 
Additionally, our data indicate that co-incubation with hBD-2 or hBD-3 in vitro induces 
an increase in the presence of FoxP3
+
 cells within the CD127
-
CD25
+
 Treg population of 
cells following 18hrs in culture. This data is consistent with the finding that, the closely 
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related homologue, murine defensin mBD-14, also induces FoxP3 expression in mouse 
CD4
+
CD25
+
 Treg cells (Navid et al., 2012). FoxP3 has been reported to be a key 
transcription factor in Treg development and suppressive function (Josefowicz et al., 
2012). Transduction of FoxP3 up-regulates expression of CD25 on the T cell surface as 
well as intracellular CTLA4 in the cytoplasm, and both markers are associated with 
Treg phenotype and function, and also triggers the suppression of IL-2 secretion (Hori 
et al., 2003, Yamaguchi et al., 2011). Our intracellular staining analysis showed that 
following 18hrs treatment with hBD-2 there was a significant increase in the percentage 
of FoxP3
+
CTLA4
+
 cells within the CD127
-
CD25
+
 Treg population. These results 
suggest that treatment with hBD-2 and 3 may induce the regulatory phenotype in human 
CD4
+
 T cells. 
 
However, surprisingly, following 42hrs in culture, we observed a significant decrease in 
the percentage of FoxP3
+
 cells in the presence of hBD-2 or hBD-3. This finding 
suggests that by this time point, treatment with hBD-2 and 3 may cause down-
regulation of FoxP3 expression in Treg cells in vitro, and this in turn may lead to 
defective Treg suppressive function of these cells in controlling effector T cell 
activation and expansion.  
 
Interestingly, when we investigated particular subsets of cells, we observed an increase 
in the number of FoxP3
+
CTLA4
+
 cells following 42hrs culture in the presence of hBD-2 
or hBD-3, suggesting that the expression of intracellular CTLA4 had been unregulated 
in these CD127
-
CD25
+
FoxP3
+
 Tregs following treatment with hBD-2 and hBD-3. 
However, as CTLA4 protein expression on Treg cell surface was below levels of 
detection, the significance of this finding is hard to evaluate. According to Tai et al. 
(2012), CTLA4 proteins expressed on Tregs are rapidly cycling between the cell surface 
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and interior, which lead to the instability of cell-surface CTLA4 protein which may alter 
the ability of interacting with co-stimulatory ligands on APCs which leads to down-
regulation of immune response. Navid et al. (2012) reported that in vitro co-incubation 
of T cells with mBD-14 could induce an up-regulation of expression of surface CTLA4 
in mouse Treg cells. However, it is still unclear whether this up-regulation in expression 
can alter Treg function. 
 
It is also possible that the up-regulation of intracellular CTLA4 expression induced by 
treatment with hBD-2 or hBD-3 may result from the presence of anti-CD28 in the 
cultures. As described previously, CTLA4-independent Treg suppression is mediated by 
CD25 and deprivation of IL-2. However, this mechanism only occurs under conditions 
using αCD28 for co-stimulation instead of APCs (Pandiyan et al., 2007), which 
circumvents CTLA4-mediated co-stimulatory blockade (Tai et al., 2012). In this study, 
we were using αCD28 as co-stimulation in the CD4+ T cell culture, which means that 
Treg suppression may occur independently of expression of CTLA4. Hence, Treg 
suppressive function may still be affected by the down-regulation of FoxP3 expression 
even though CTLA4 expression is apparently increased inside the cells. In this case, an 
in vitro suppressor function assay of Treg cells is required to be performed in order to 
investigate the ability of Tregs to induce suppression of effector T cells following 
treatment with hBD-2 and hBD-3 (Chapter 6).  
 
Classically, thymic derived Tregs (tTregs) have been considered to be a distinct lineage 
from effector T cells. In the lineage perspective model, tTregs are regarded as self-
reactive T cells which escaped from negative selection in the thymus, and this T cell 
phenotype is selected to control self-reactive naïve T cells in the periphery (Josefowicz 
et al., 2012, Ono and Tanaka, 2016).  However, a recently paper by Ono and Tanaka 
61 
 
(2016) suggested that the induction of Tregs may occur as a natural consequence of T 
cell activation and may provide a mechanism whereby the immune response may be 
negatively regulated in terms of T cell activation, thus providing a „feedback control 
mechanism‟. In this model, some of the activated T cells generate FoxP3- memory-like 
T cells (or T effector cells) which act as positive regulators to induce immune response, 
while some of the activated T cells are induced to express FoxP3 (Tregs) which then 
allows them to compete the binding sites on APCs with FoxP3
-
 Teff in order to delay T 
cell activation (Ono and Tanaka, 2016). According to this hypothesis, self-antigens or 
previously recognized antigens can induce a positive immune response by Teffs and a 
negative regulation by Tregs. This model suggested that upon TCR activation, both 
FoxP3
-
 Teff response and FoxP3
+
 Treg regulation can be triggered together, and 
enhanced TCR signaling can induce both FoxP3
-
 Teff response and FoxP3
+
 Treg 
regulation. 
 
In summary, FoxP3 expression was regarded to be a consequence of T cell activation 
and provides a negative feedback control on human T cell activation (Ono and Tanaka, 
2016). Interestingly, FoxP3 was reported to have the capacity to bind to various 
transcription factors in order to induce the activation in conventional T cells and to 
regulate their functions (Ono and Tanaka, 2016, Josefowicz et al., 2012). It has also 
been suggested that IL-2 secreted by activated T cells may induce and prolong FoxP3 
expression in Tregs, while the expressed FoxP3 inhibits IL-2 production by repressing 
NFκB and NFAT transactivation reporters (Ono and Tanaka, 2016, Hench and Su, 2011, 
Smith and Popmihajlov, 2008). In our study, we found that treatment with hBD-2 and 
hBD-3 increased FoxP3 expression in Treg cells following 18hrs in culture together 
with an activation stimulus, suggesting an enhanced differentiation of Tregs following 
delivery of an activation stimulus together with hBD-2 or hBD-3. This induction of 
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FoxP3 expression may occur as the result of the ability of treatment with hBD-2 and 3 
to induce enhanced IL-2 production by 18hrs. By 42hrs, treatment with hBD-2 or hBD-
3 induced a decrease of FoxP3
+
 Treg cells which may suggest a weakened control of T 
cell activation and subsequently leading to the enhanced positive feedback via effector 
T cells.  
 
Taken together, when considering which hypothesis of Treg differentiation best fits the 
data presented in this chapter, it would seem that  the point of view of a feedback 
control perspective (Ono and Tanaka, 2016) appears to fit best. Treatment with hBD-2 
and hBD-3 may induce FoxP3 expression, following, or in parallel with, an 
enhancement in T cell activation and therefore induce both Teff response and Treg 
response simultaneously.  
 
Considering the well documented plasticity of T effector cells in the periphery in 
response to the local environment in which the T cell is found, the down-regulation of 
FoxP3 expression following co-culture with hBD-2 or hBD-3 for 42hrs implies a loss of 
the Treg phenotype and its associated functions. It might also suggest the differentiation 
towards an altered T cell immune response that might arise due to the influence of the 
local environment. For example, in the case where an infection has triggered an 
inflammatory immune response resulting in inflammation and an up-regulation of 
expression of the hBDs. 
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Figure 4.10 A proposed schematic model summarising the key findings in Chapter 4. A. 
hBD-2 or hBD-3 treatment enhances human CD4
+
 T cell activation. B. hBD-2 or hBD-3 
treatment enhances human CD4
+
 T cell proliferation. C. hBD-2 or hBD-3 treatment up-
regulates the induction of CD127
-
CD25
+
FoxP3
+
 Treg population at 18hrs, however, 
down-regulates the percentage of CD127
-
CD25
+
FoxP3
+
 Treg population following 
42hrs treatment. 
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4.4 Conclusion  
In this chapter, we discussed the effect of treatment of CD4 T cells with hBD-2 and 3 
on activation and proliferation in vitro. Our data suggest that treatment of CD4
+
 T cells 
with hBD-2 or hBD-3 leads to an increase in the presence of CD4
+
CD69
+
CD25
+
 and 
CD4
+
CD69
-
CD25
+
 T cell subsets  following  18hrs and 42hrs in culture. We also 
observed an enhanced rate of CD4
+
 T cell proliferation following 96hrs in the presence 
of hBD-2 or hBD-3 and this was accompanied by an increased IL-2 production in the 
supernatant of the treated CD4
+
 T cell cultures. We also showed using intracellular 
staining that the presence of FoxP3
+
CD4
+
CD127
-
CD25
+
 Treg cell was increased 
following treatment with hBD-2 and hBD-3 for 18hrs but the presence of this 
FoxP3
+
CD4
+
CD127
-
CD25
+
 cellular subset was reduced by 42hrs in culture. This data is 
consistent with the finding reported in Chapter 3 using human PBMCs, suggesting that 
this is a CD4
+
 T cell intrinsic effect. Additional to our observations regarding FoxP3 
expression, we also investigated intracellular CTLA4 expression in CD4
+
CD127
-
CD25
+
 
Tregs. Although there was an increase in percentage representation of FoxP3
+
CTLA4
+
 
cells within the CD4
+
CD127
-
CD25
+
 population of Treg cells, further investigation is 
still required in order to assess stability and plasticity of the Treg phenotype following 
treatment with hBD-2 and 3. Thus, in the next chapter, we will investigate the role of 
hBD-2 and 3 in driving human CD4
+
 T cell plasticity.   
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Chapter 5: Regulation of human CD4
+
 T cell plasticity 
following treatment with hBD-2 and hBD-3 
 
5.1 Introduction 
Differentiation of CD4
+
 T helper cells into distinct functional phenotypes is crucial for 
immune homeostasis. These subsets are defined as separate lineages based on the 
expression of selective signature cytokines and master transcriptional factors (Zhou et 
al., 2009, Lazarevic et al., 2013). Upon antigen presentation, CD4
+
naïve T cell can 
polarize to become one of a variety of different effector phenotypes, including Th1, Th2, 
Th17, follicular T helper cells (Tfh) and Treg cells. The direction of polarisation is 
determined and regulated by the cytokines in the microenvironment and the strength of 
TCR activation signal (Zhou et al., 2009).   
 
Recent studies have demonstrated that hBDs can play a role in the regulation of T cell 
cytokine production. It is reported that hBD-2 can enhance mRNA level and secretion 
of IFN-γ, TNF-α, IL-1β, IL-6, IL-10and IL-22, and reduce those of IL-17 in αCD3/28-
stimulated CD3
+
 T cells (Kanda et al., 2011). Interestingly, these are all cytokines that 
display either pro or anti-inflammatory effect and as such, it would be expected that 
they be secreted at an inflamed site. 
 
Additionally, hBD-3 has been reported to induce IL-2 and IL-10 production, but not 
IFN-γ (Meisch et al., 2013). All three cytokines are involved in regulating T cell 
function and differentiation. These studies also demonstrated that hBD-2 and hBD-3 are 
capable of regulating STAT3 and STAT1 phosphorylation, respectively, two important 
regulators of helper T cell differentiation and functions (Kanda et al., 2011, Meisch et 
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al., 2013, Yoshimura et al., 2012). Several cytokines, in particular, have been 
implicated in driving T cell plasticity. For example, IL-6 together with TGFβ has been 
shown to be involved in Th17 differentiation (Korn et al., 2009). IL-10 has been shown 
to induce Treg differentiation (Bilate and Lafaille, 2012), while IFN-γ can induce Th1 
differentiation (Cope et al., 2011). Hence, we hypothesized that hBD-2 and hBD-3 may 
be capable of regulating the differentiation of these T cell subsets by modulating the 
expression of these cytokines. 
 
Both human and murine β-defensins have also been shown to play a role in T cell 
mediated immune-regulation. Navid et al. (2012) demonstrated that mBD-14 was 
involved in the induction of differentiation of mouse Treg cells. In their research, the 
treatment of CD4
+
 T cells with mBD-14 in mouse can induce expression of the 
molecular signature of Tregs, such as FoxP3, CTLA4 and neuropilin expression. In 
addition, the injection of mBD-14 into C57BL/6 mice was shown to suppress the 
induction of contact hypersensitivity by inducing the differentiation of Ag-specific 
Tregs in an IL-10 dependent fashion (Navid et al., 2012).  
 
Taken together, these studies suggest that β-defensins have the capacity play a role in 
the regulation of T cell polarisation and plasticity. However, little is known about the 
molecules involved in driving this process. In this chapter, we show that treatment of 
human CD4
+
 T cells with hBD-2 and hBD-3 is capable of regulating expression of the 
master transcriptional factors in Th1, Th17 and Treg cells.  
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5.2 Results 
5.2.1 Intracellular staining of RORγt, T-bet and FoxP3 in human CD4+ T cells culture 
at 18hrs 
In Chapter 4, we demonstrated that treatment of purified CD4
+
 T cells with hBD-2 and 
hBD-3 can induce T effector cell activation and proliferation whilst also apparently 
inducing Treg cells expansion. Based on this apparently conflicting data, we 
hypothesized that treatment of T cells with hBD2 and 3 might induce differentiation of 
Treg cells but, that subsequently, these cells lose their ability to suppress the 
differentiation of Teff cells. To determine the identity of the T cells following treatment, 
intracellular staining was undertaken, analysing the expression of T-bet, RORγt and 
FoxP3, as the hallmark transcriptional factors of Th1, Th17 and Tregs respectively 
(Josefowicz et al., 2012, Korn et al., 2009, Lazarevic et al., 2013). As shown in Figure 
5.1, when focussing on the CD69
+
CD25
+
 T cell subset, there was a significant increase 
in the presence of RORγt+T-bet+ T cells but not RORγt+T-bet- or RORγt-T-bet+ subsets, 
following treatment with hBD-2 and hBD-3 for 18hrs in culture, suggesting that there is 
an induction of differentiation of a T cell subset which displays characteristics of both 
Th1 and Th17 cell (Figure 5.2A). The expansion of the RORγt+T-bet+ T cell subset 
represents an expansion of an intermediate phenotype (Th1/17) in between Th1 and 
Th17 (Geginat et al., 2013). It has been suggested that, a double positive Th1/Th17 cell 
is capable of producing pro-inflammatory cytokines, including IFN-γ and IL-17 
(Kleinewietfeld and Hafler, 2013). Also, according to the study by Lee et al. (2012), T-
bet can play an essential part in pathogenic Th17 cells induction. This suggests that the 
co-incubation with hBD-2 or hBD-3 may induce a more pro-inflammatory phenotype, 
Th1/17, by 18hrs and the induction of T-bet
+
 may cause the pathogenicity of Th17 cells. 
This finding is consistent with a role for the defensins in inducing autoimmune 
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inflammatory conditions such as IBD and colitis (Ramasundara et al., 2009, Ho et al., 
2013). 
 
Additionally, we found that when analysing the CD69
-
CD25
+
 cells (Figure 5.1), which 
we expected to contain more Treg cells, we, once again, observed a significant increase 
of RORγt+T-bet+ dual expressing cells when co-incubated with hBD-2 or hBD-3 
(p=0.11) (Figure 5.2A). There was also a significant increase or close to significant 
increase in this CD69
-
CD25
+
 subset towards increased expression of RORγt-T-bet+ 
putative Th1 T cells in the presence of hBD-2 and hBD-3 (p=0.07) (Figure 5.2A). 
Further characterization of RORγt and T-bet expression also performed in 
CD25
+
CD127
-
 Treg cells revealed that there was a is significant increase of RORγt-
FoxP3
+
 phenotype in these CD25
+
CD127
-
 Treg subset when co-cultured with hBD-2 or 
hBD-3. This suggested co-incubation with hBD-2 or hBD-3 induces an increase in the 
number of FoxP3
+
 cells within the CD25
+
CD127
-
 population of Tregs but additionally, 
some of these FoxP3
+
 cells also appeared to express T-bet (Figure 5.2B). This is 
consistent with the finding in Chapter 4, in which we reported a significant increase of 
the percentage of FoxP3 staining in Tregs by 18hrs. In addition, we also found a trend 
towards a decrease of in the presence of RORγt+FoxP3- subset when treated with hBD-2, 
and a significant decrease of the RORγt+FoxP3- subset when treated with hBD-3, 
whereas the percentage of T-bet
+
FoxP3
+
 cells were significantly increased when treated 
with hBD-2 or hBD-3. This suggests that, by 18hrs in culture, CD25
+
CD127
-
 Treg may 
differentiate into an intermediate phenotype (Th1/Treg, T-bet
+
FoxP3
+
 cells, Figure 
5.2B) that has characteristics of both Th1 and Treg cell following treatment with hBD-2 
or hBD-3. These so-called Th1-like Treg cells observed with treatment with hBD-2 and 
hBD-3 has been reported to secret IFN-γ (Dominguez-Villar et al., 2011), which are 
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also associated with several autoimmune disease in humans, such as Type I diabetes 
(T1D) (Kleinewietfeld and Hafler, 2013). 
 
 
Figure 5.1 Gating strategy for intracellular staining of RORγt and T-bet staining in 
CD69
+
CD25
+
 T effector cells or CD69
-
CD25
+
 Treg cells following 18hrs culture. 
Purified human CD4
+
 T cells were stimulated using αCD3/28 antibodies and treated 
with hBD-2 (10µg/ml) or hBD-3 (10µg/ml) for 18hrs. Gating was done on the 
CD69
+
CD25
+
 subset or CD69
-
CD25
+
 subset, within these two gates, the percentages of 
RORγt+T-bet-, RORγt+T-bet+, RORγt-T-bet+ cells were measured respectively. 
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Figure 5.2 Intracellular staining of RORγt, T-bet and Foxp3 of human CD4+ T cells at 
18hrs with the treatment of hBD-2 or hBD-3. A. Fold change analysis performed 
according to the percentage of different subsets collected from at least 5 independent 
experiments (n=5). B. Fold change analysis performed according to the percentage of 
different subsets gating on Treg population from 5 independent experiments (n=5). The 
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significance of the differences observed in fold changes was assessed by One-way 
ANOVA, *p<0.05.  
 
5.2.2 Intracellular staining of RORγt, T-bet and FoxP3 in human CD4+ T cells culture 
at 42hrs. 
In addition to the data observed at 18hrs, we investigated the effect of treatment co-
incubation with hBD-2 and hBD-3 for 42hrs on T cell function (Figure 5.3). In contrast 
to the 18hrs data, there was an increased population of RORγt+T-bet- effector T cells in 
the presence of hBD-2 (p=0.08) or hBD-3 (p=0.06) (Figure 5.4A) possibly suggesting 
the differentiation of the Th1/Th17 cell observed at 18hrs towards the Th17 phenotype 
at this later time point. Also, when analysing the CD69
-
CD25
+
 Treg cell population, 
there was a similar significant increase of RORγt+T-bet- subset in the presence of hBD-
3 (Figure 5.4A). This suggests that, following 42hrs in co-culture, Treg cells may be 
induced to differentiate to become a RORγt+ Treg phenotype which is capable of further 
differentiation into an IL-17 producing effector T cells (Mercer et al., 2014). 
Furthermore, when analysing the effect of hBD-3 treatment on CD25
+
CD127
-
 Treg 
cells, we found a significant increase of RORγt+Foxp3- and T-bet+Foxp3- subsets and 
significant decrease of RORγt-Foxp3+ and T-bet-Foxp3+ subsets (Figure 5.4B) 
suggesting a loss of FoxP3 expression in these treated T cells. This data suggests that 
hBD-3 may induce differentiation away from Treg phenotype towards Th17 and Th1 
phenotype. However, when analysing the presence of Tregs form following hBD-2 
treatment, we only found a significant induction of T-bet
+
Foxp3
-
 subset, and a trend of 
increase in RORγt+Foxp3- (Figure 5.4 B). Interestingly, a closely significant difference 
between hBD-2 and hBD-3 in the induction of RORγt+Foxp3- subset may reveal the 
difference between hBD-2 and hBD-3 that hBD-3 is more capable of promoting Th17 
differentiation or maintaining the stability of Th17 phenotype. It is consistent with the 
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data that we obtained using our IL-17A ELISA which data showed that treatment with 
hBD-3, but not hBD-2 significantly induced IL-17A production by CD4
+
 T cells in the 
culture (Figure 5.5). Because IL-6 plays a key role in driving Th17 differentiation as 
well as IL-17A production, it became important to investigate whether the expression of 
this cytokine is regulated by either treatment with hBD-2 or hBD-3. We then performed 
an IL-6 ELISA and interestingly, we found that hBD-3 but not hBD-2 induced a 
significant increase of IL-6 secretion, this data is consistent with the finding that IL-17A 
secretion is also increased following treatment with hBD3 but not hBD2 suggesting that 
treatment with hBD-3 specifically induces the differentiation of a Th17 like phenotype, 
in part, by up regulating expression of IL-6 (Figure 5.5). However, whilst hBD-2 also 
drives the differentiation of a Th17 like phenotype this may not be a pathogenic Th17 
phenotype as there is no increase in IL-17A secretion observed. Additionally, we found 
that both hBD-2 and hBD-3 treatment significantly increased the level of IL-10 in the 
supernatant of CD4
+
 T cell culture, suggesting that hBD-2 and hBD-3 are capable of 
inducing the anti-inflammatory factor that can negatively regulate immune response.    
 
 In addition, we found that both hBD-2 and hBD-3 are capable of inducing IL-10 
production in purified CD4
+
 T cells. It is consistent with the finding that hBD-2 induced 
IL-10 production in human CD3
+
 T cells (Kanda et al., 2011), however, it was not 
found that the level of IL-10 was significantly changed by the treatment of hBD-3 
(Kanda and Watanabe, 2012). Because CD3
+
 T cells consist of CD4
+
 T cells, CD8
+
 T 
cells, NKT cells and HLA DR
+
 T cells (Orru et al., 2013), in future studies, we should 
further characterize the effect of  hBD-2 and hBD-3 on the other T cell subsets. 
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Figure 5.3 Gating strategy for intracellular staining of RORγt and T-bet in 
CD69
+
CD25
+
 T effector cells or CD69
-
CD25
+
 Treg cells following 42hrs culture. 
Purified human CD4
+
 T cells were stimulated using αCD3/28 antibodies and treated 
with hBD-2 (10µg/ml) or hBD-3 (10µg/ml) for 42hrs. Gating on the CD69
+
CD25
+
 
subset or CD69
-
CD25
+
 subset, the percentages of RORγt+T-bet-, RORγt+T-bet+, RORγt-
T-bet
+
 cells were measured respectively. 
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Figure 5.4 Intracellular staining of RORγt, T-bet and Foxp3 of human CD4+ T cells at 
42hrs with the treatment of hBD-2 or hBD-3. A. Fold change analysis performed 
according to the percentage of different subsets collected from at least 5 independent 
experiments (n=5). B. Fold change analysis performed according to the percentage of 
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different subsets gating on Treg population from 5 independent experiments (n=5). The 
significance of the differences observed in fold changes was assessed by One-way 
ANOVA, *p<0.05, **p<0.01. 
 
 
Figure 5.5 Cytokine ELISA for IL-6, IL-10 and IL-17A production in the supernatants 
of T cell culture. One-way ANOVA was performed for significant analysis with Turkey 
as post-test. Data were collected from 5 independent experiments (n=5). *p<0.05, 
**p<0.01. 
 
5.2.3 Phenotyping of CD4+CD25+ T cells in the presence or absence of hBD-2 and 3 
To understand the effect on plasticity of treatment of activated CD4
+
 T cell co-cultured 
with hBD-2 or hBD-3, CD4
+
CD25
+ 
T cells were gated on, and analysed following for 
expression of T-bet, RORγt and FoxP3 following intracellular staining. In Figure 5.6, 
phenotypes in of the stimulated control were set to 1 fold (blue line) and the fold 
changes of each phenotype following treatment with in the presence of hBD-2 (red line) 
and hBD-3 (green line) are displayed in the radar charts. The upper left radar chart 
shows that, following 18hrs co-culture with hBD-2 or 3, activated CD4
+
 T cells tends 
appear to differentiate towards a Th1-like phenotype regarding in respect  to the 
expression of the transcriptional factor, so that the distribution of the hexagon extends 
to the Th1 side and not to the, whereas Th17 proportion is hold backside. 
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However, interestingly, following 42hrs co-culture with hBD-2 (Figure 5.4, upper right), 
the differentiation of CD4
+
CD25
+
 T cell moves from a Th1-like phenotype to  a Th17-
like phenotype and following treatment with hBD3 the CD4 T cells take on a more 
TH17/Treg type phenotype. It has been reported in the literature that IL-6 is able to 
induce Th1 and Treg cells to differentiate to become Th17 cells (Muranski and Restifo, 
2013). Compared to hBD-2, hBD-3 induced CD4
+
CD25
+
 T cell differentiation towards 
Th17/Treg phenotype and this was accompanied by an increase in IL-6 and IL-17 
secretion. 
 
Figure 5.6 Phenotypes of human CD4
+
 T cell in the presence or absence of hBD-2 and 
hBD-3. The radar charts show the fold change of different T cell subsets characterized 
in activated CD4
+
CD25
+
 T cells. Data were collected from 5 independent experiments 
(n=5). 
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5.3 Discussion 
Previously in Chapter 4, we demonstrated that co-culture of human purified CD4
+
 T 
cells with hBD-2 together with αCD3/28 causes an up-regulation in the numbers of 
CD69
+
CD25
+
 Teff and CD69
-
CD25
+
 Treg cells at 18hrs and these numbers remain 
increasing following 42hrs in culture. However, we also showed that co-culture with 
hBD-2 and hBD-3 resulted in a significant increase in the percentage of proliferated 
CD4
+
 T cells suggesting a positive effect on the rate of proliferation observed in T cells 
which data is seemingly at odds with the previous finding that treatment with hBD-2 
appears to induce the differentiation of Treg cells. 
 
Recent studies have demonstrated that there is an “unexpected” plasticity between Treg 
and Teff cells (Kleinewietfeld and Hafler, 2013). Treg cells are capable of converting 
into Th1-like cells or Th17-like cells in which RORγt or T-bet is expressed respectively. 
When this occurs the effects are reported to be pro-inflammatory (Zhou et al., 2009, 
Nakayamada et al., 2012, Soler and McCormick, 2011). Additionally, this plasticity can 
also be determined by the strength and duration of T cell stimulation signals (Miskov-
Zivanov et al., 2013). It is still unclear whether hBDs play a role in these processes. In 
Kanda‟s research (2011), it was demonstrated that treatment of T cells with hBD-2 
could induce secretion of IFN-γ, IL-1β and IL-6, but suppress IL-17 production 
suggesting a role for hBD-2 in T cell polarisation. IFN-γ is a signature cytokine of Th1 
cells and IL-1β and IL-6 can induce Th17 differentiation but with no increase observed 
in this study in IL-17 secretion it might suggest that differentiation towards Th1 
phenotype is a dominant of treatment of T cells with hBD-2. In addition, any role for 
hBD-2 in inducing the plasticity of Tregs towards another phenotype with a consequent 
loss of suppressive function needs to be investigated.  
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Based on these findings, we undertook intracellular staining analysis for the 
characterisation of the master transcriptional factor of Th1, Th17 and Treg cells. The 
data presented here suggest that treatment with hBD-2 and hBD-3 induced effector T 
cells to differentiate into RORγt+T-bet+ Th1/17 phenotype following 18hrs in culture. 
RORγt+T-bet+ effector T cells are reported to appear in response to viral infection 
(Hegazy et al., 2010), but this phenotype is also demonstrated to drive chronic 
inflammation in autoimmune disease (Geginat et al., 2013). This suggests that hBD-2 
and hBD-3 not only have an anti-microbial effect, but also have the capacity to induce 
effector T cells to differentiate towards a more pro-inflammatory phenotype with 
pathogenic capability such as Th17 cells.  
 
In addition, when considering the data obtained at following 18hrs in culture, we 
observed that treatment the co-culture with hBD-2 or hBD-3 may induce Treg cells 
exhibiting to lose in FoxP3 expression and a gain in T-bet expression. This finding 
suggests that hBD-2 and hBD-3 can not only induce Teff cells to differentiate into 
Th1/17 pro-inflammatory phenotype, but also trigger Treg plasticity by converting into 
a Th1-like phenotype, which may cause the loss of their immune-regulatory function 
and secretion of IFN-γ. This finding is consistent with a role for the defensins in 
inducing autoimmune disease, such as psoriasis and IBD (de Jongh et al., 2005, Ho et 
al., 2013). 
 
Despite the fact that T-bet is the master control gene, expression of which drives Th1 
cell differentiation and function, it is also reported to play an essential role in Th17 
differentiation. It has been revealed that T-bet expression can induce endogenous TGF-
β3 expression in Th17 cells and modulate other factors to drive Th17 conversion into a 
pathogenic phenotype. This makes T-bet expression part of the molecular signature of 
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pathogenic Th17 cells (Lee et al., 2012). Accordingly, in autoimmune disease, Treg 
cells may lose FoxP3 expression, but increase RORγt expression and produce IL-17 
(Mercer et al., 2014, Joller and Kuchroo, 2014). It is unclear in the literature whether 
hBD-2 or hBD-3 can induce Treg cells to differentiate into Th17 phenotypes. We found 
that treatment with hBD-2 or hBD-3 enhanced T-bet expression in both Teff and Tregs 
by 18hrs. We then observed a significant increase of RORγt expression in both Teff and 
Tregs by 42hrs in culture in the presence of hBD-2 and hBD-3. This expression pattern 
is consistent with a Th17-like phenotype in both effector T cells and Tregs. This 
suggests that with further treatment with hBD-2 or hBD-3, CD4
+
 T cells may be 
converted via a Th1-like intermediary cell into a Th17-like T cell. However, 
surprisingly, we observed that only co-culture with hBD-3 induced RORγt expression in 
Treg cells but hBD-2 did not. Consistent with this phenomenon, hBD-3 did, but hBD-2 
did not, induce IL-17A production following 42hrs in culture. As IL-6 is the key factor 
to drive Th17 differentiation, IL-6 secretion in the cultures was measured and the data 
suggested that co-culture with hBD-3 induced an increase in IL-6 production which 
would in turn, lead to increased IL-17 secretion. Taken together, these data demonstrate 
that treatment with hBD-2 and hBD-3 may modify the effector T cells immune response 
and also drive Treg cells to lose Foxp3 expression thus also influencing the homeostasis 
of the immune response. The consequences of this latter finding may lead to defective 
Treg suppression and convert Tregs into Th1-like or Th17-like phenotype which could 
potentially drive further inflammation. 
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Figure 5.7 A proposed schematic model summarising the key findings in Chapter 5. A 
and B. RORγt and T-bet expression in CD69+CD25+ T cells or CD69-CD25+ T cells. C. 
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The plasticity of Treg cells characterised by RORγt and T-bet expression. n.s. denotes 
no significant difference. 
 
5.4 Conclusion 
In summary, we report a role of hBD-2 and hBD-3 in human CD4
+
 T cells activation, 
differentiation and proliferation. Our in vitro study demonstrated that treatment with 
hBD-2 and hBD-3 could not only induce Teff cells to differentiate into RORγt+T-bet+ 
cells, they could also trigger Treg cells to express RORγt and T-bet which may induce 
Tregs plasticity converting from Treg to Th1/17-like phenotype by 18hrs post activation 
stimulus. By 42hrs, treatment with hBD-2 and hBD-3 induced both effector and Treg 
cells to differentiate towards a Th17-like phenotype and away from the Th1-like 
phenotype. Compared with hBD-2, treatment with hBD-3 induced the appearance of 
Treg cells expressing more RORγt which in turn produced IL-17A. Consistent with this, 
it was treatment with hBD-3 but not hBD-2 that induced the production of IL-17A as 
well as IL-6, which is a key inducer of Th17 polarization in T cells.  
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Chapter 6: Function assay of human CD4
+
CD25
+
CD127- Treg 
cells in the presence of hBD-2 in vitro 
 
6.1 Introduction 
Recent studies have provided strong evidence that CD4
+
CD25
+
CD127
-
FoxP3
+
 Treg 
cells appear to be critical in regulating immune response to self-antigens and are able 
suppress the proliferation of co-cultured effector T cells (Teffs) (Hartigan-O'Connor et 
al., 2007, Liu et al., 2006).  
 
As FoxP3
+
 Treg cells play an important role in suppressing the activation and 
proliferation of Teffs, impaired Treg regulation may result in the failure of immune 
suppression and contribute to the development of autoimmunity (Costantino et al., 
2008). Accordingly, possible causes of impaired Treg-mediated suppression leading to 
autoimmunity include: 1) defective Treg function; 2) inadequate numbers of Treg cells 
and 3) resistance of Teff cells to the suppressive function of Tregs (Buckner, 2010). 
Either just one, or a combination of these events, may lead to defective Treg-mediated 
suppression. 
 
In Chapter 5, we demonstrated that the treatment of CD4
+
 T cells with hBD-2 induced 
human Treg cells to differentiate into T-bet
+
 Th1-like phenotype following 18hrs in 
culture. In addition, following 42hrs co-culture with hBD-2, Treg cells were induced to 
differentiate into RORγt+ Th17-like phenotype. Based on these results, we hypothesized 
that the treatment of CD4
+
 T cells with hBD-2 may cause defective Treg function which 
leads to the loss of the suppression on Teff cell activation and proliferation. Thus, in 
this chapter, we used an in vitro suppression assay to test this possibility.  
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6.2 Results 
6.2.1 Treatment of human CD4+ T cells with hBD-2 may not only enhance Teff cell 
resistance to suppression but also result in a defective ability of Treg cell to mediate 
suppression. 
To investigate the capability of hBD-2 treated Tregs to mediate suppressive action on 
the proliferation of Teff cell, a Treg suppression assay was developed as shown in 
Figure 6.1. According to previously published studies documenting the phenotypic 
characterization of Treg subsets, potent suppressor Tregs are identified as the 
CD4
+
CD25
+
CD127
-
 subset contained within human peripheral blood. These are distinct 
from Teff cells which are CD4
+
CD25
-
CD127
+
 (Figure 6.1A) (Liu et al., 2006). 
Following FACS sorting of these two subsets of cells, Teff (CFSE labelled) and Treg 
cells were incubated in the presence and absence of hBD-2 for 4hrs. Then, Treg cells 
were cultured together with Teff cells at Teff/Treg ratio of 1:1 and stimulated with 
αCD3/28 Dynabeads for 4ds. The various combinations of treated and untreated Tregs 
and Teff cells used are shown as Figure 6.1B. The effect of hBD-2 on Treg-induced 
suppression, or Teff resistance to suppression, was compared in each case with the data 
obtained using non-treated (N) populations of cells, Teff(N)+Treg(N) combination. As 
shown in Figure 7A, typically, the proliferation of Teff(N) alone is 61.8%. When 
Teff(N) are co-cultured with Treg(N), the proliferation of Teff is typically decreased 
from 61.8% to 45.8%. This suggests that the proliferation of Teff cells was suppressed 
by Treg cells as expected and that the assay is working. Interestingly, Teff(T) cell 
proliferation increased from 61.8% to 66.9%. This suggests that hBD-2 treatment of this 
sorted population alone can induce Teff proliferation, which is consistent with previous 
results shown in Chapter 4. In addition, the percentage of proliferation of Teff in the 
case of the  Teff(T)+Treg(N) combination increased from 45.8% to 64.4%, compared 
with Teff(N)+Treg(N) (Figure 6.2). This finding suggests that co-incubation of Teff 
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cells with hBD-2 may enhance the resistance of these Teff cells to Treg mediated 
suppression. Moreover, when considering the Teff(N)+Treg(T) combination, the 
proliferation of Teffs increased from 45.8% to 64.6%. This suggests that treatment of 
Treg cells with hBD-2 may cause these Treg cells to lose their ability to suppress Teff 
proliferation. 
 
 In order to carry out a more detailed analysis of the effects of treatment of Tregs and 
Teff cells with hBD2, statistical analysis was carried out on the percentage of cells that 
had undergone, 2,3,4 and 5 cycles of T cell proliferation. The data shown suggests that 
there is a significant increase of proliferation observed in Teff cells that had undergone 
2-5 cycles following their treatment with hBD2 and in the presence of untreated Tregs;  
Teff(T)+Treg(N). We also found a significant increase in the number of Teff cells that 
had undergone 2 and 3 rounds of proliferation in the presence of treated Treg cells: 
Teff(N)+Treg(T). In respect the cells that had undergone 4 or 5 cycles there is a trend 
towards increasing proliferation but the differences are not significant. Surprisingly, we 
did not observe an additive effect towards increased proliferation when both treated 
Teff and Treg cells were cultured together: Teff(T)+Treg(T). This may be due to the 
possibility that there is an increase in cell death induced by hBD-2 when both treated 
cells are co-cultured. These data demonstrated that treatment with hBD-2 may cause 
Treg cells to partially lose their ability to mediate Teff cell suppression as well as cause 
Teff cells to be resistant to Treg-mediated inhibition. This is consistent with our finding 
that hBD-2 induces human CD4
+
 T cell proliferation.  
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Table 6.1 Codes for different population of Teff and Treg cells with or without 
treatment of hBD-2. 
Codes Description 
Teff(N) 
Effector T cells which were NOT treated with hBD-2 
Teff(T) 
Effector T cells which were treated with hBD-2 
Treg(N) 
Regulatory T cells which were NOT treated with hBD-2 
Treg(T) 
Regulatory T cells which were treated with hBD-2 
 
 
Figure 6.1 Cell sorting strategy and diagram of the experiment design of the experiment 
analysing the effects of hBD-2 treatment on Treg suppressive function. A. FACS 
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sorting of Teff cells and Treg cells. Gates were set according to the results obtained 
using single stained controls. Interphase cells which may contain CD127
+
CD25
+
 cells 
were excluded in order to obtain a pure population of Teff cells and Treg cells. B. 
Diagram of the experimental design of Treg suppression assay.  
 
 
 
Figure 6.2 The suppression of proliferation of CFSE labelled Teff by Tregs. 
Histograms showing proliferation of CFSE labelled Teff cells. Teff and Treg cells were 
co-cultured and analysed for the ability of the Tregs to suppress the proliferation of the 
CFSE labelled Teff cells. Data was collected after 4ds in culture. Teff cells were gated 
on as the CFSE
+
 population. The percentage of proliferating cells is shown (reduced 
CFSE fluorescence indicates proliferation). 
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Figure 6.3 Statistical analysis of fold changes in total number of Teff cells in 
proliferation or those cells having undergone 2, 3, 4 or 5 cycles only. Bar graphs 
representing the fold changes of percentage of undergone cycles in Teff proliferation. 
Data were collected from 7 independent experiments (n=7). Statistical significance: 
*p<0.05. 
 
6.3 Discussion 
In Chapter 5, we demonstrated that, using intracellular staining for the master 
transcriptional factor of Th1, Th17 and Treg cells, hBD-2 treatment in CD4
+
 T cells 
culture induced the differentiation of T cells expressing more than one master 
transcriptional factor. The data presented in Chapter 5 suggest that hBD-2 induced Treg 
cells to differentiate into T-bet
+
FoxP3
+
 Th1/Treg phenotype following 18hrs in culture. 
This finding suggests that hBD-2 treatment may induce T cell plasticity by inducing 
Treg cells to differentiate towards a subset which is potentially an IFN-γ producing 
Th1-like phenotype while the suppressive activity of the developing Treg population is 
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suppressed (Kleinewietfeld and Hafler, 2013). By the later time point of 42hrs treatment 
of CD4
+
 T cells with hBD-2 may also induce Teff cells to differentiate towards a more 
pro-inflammatory phenotype with possible pathogenic capability such as Th17 cells. 
These possibilities are consistent with a role for the defensins in inducing autoimmune 
disease, such as IBD and colitis. 
 
A recent study by Navid et al. (2012) indicated that a mouse defensin mBD-14 can 
induce FoxP3, CTLA-4 and Nrp-1 expression in mouse Tregs. However, the induction 
of FoxP3, CTLA-4 and Nrp-1 expression is only thought to correlate with the induction 
of Treg phenotype but does not necessarily equate to an enhancement of Treg function. 
Hence, we developed a Treg suppression assay using hBD-2 treated or non-treated 
Tregs and Teff to investigate any effect of treatment of these cells with hBD-2 on both 
Treg suppressive function and the resistance of Teff against Treg inhibition. It was our 
original aim to further characterise whether hBD-2 could cause Treg cells to be 
incapable of properly inhibiting Teff proliferation, or alternatively, to induce resistance 
of Teff to Treg cell mediated inhibition thus explaining our increase in proliferation of 
effector T cells in the presence of hBD2. In our study, the data demonstrated that, with 
Teff:Treg ratio of 1:1, hBD-2 treated Tregs were incapable of mediating proper 
suppressive function compare to non-treated Tregs. Additionally, hBD-2 treated Teffs 
were observed to be partially resistant to the suppression function of Tregs. Together, 
these data suggest that treatment with hBD-2 may indeed dampen down Treg 
suppressive ability whilst simultaneously increasing Teff resistance to Treg 
immunoregulation in vitro. Interestingly, Kanda et al. (2011) suggested that treatment 
with hBD-2 is able to induce the phosphorylation of JNK, ERK, and Akt in human T 
cells. It is suggested that PI3K-Akt signalling activated by CD28 can inhibit FoxP3 
expression, which leads to the loss of stability of Treg differentiation and function (Luo 
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and Li, 2013). These findings raise the possibility that treatment with hBD-2 may 
influence the CD28 co-stimulation pathway to regulate FoxP3 expression. 
 
In Chapter 5, we reported our finding that the treatment of CD4
+
 T cells with hBD-2 
increased IL-10 production following 42hrs in culture. This phenomenon suggests an 
induction of Treg function. However, according to the review by Shevach (2009), it is 
pointed out that in vitro Treg suppression may not be mediated only by IL-10 but may 
require the presence of additional factors. This may explain the conflict between 
increased IL-10 production and decreased Treg mediated suppression. It is reported that 
IL-35 and galectin-1 may be the soluble suppressor cytokines which mediate Treg 
suppression in vitro (Shevach, 2009). IL-35 is a member of the IL-12 heterodimeric 
cytokine family and consists of two subunit encoded by two different genes, Ebi3 
(express a subunit of IL-27) and Il12a (express a subunit of IL-12). It has been shown 
that expression of both Ebi3 and Il12a mRNA is up-regulated in Treg cells that perform 
normal suppressive function. Interestingly, Treg cells isolated from both Ebi3
-/-
 and 
Il12a
-/-
 knockout mice  exhibit repressed inhibitory activity in vitro when Teff cells are 
stimulated with αCD3/28 coated beads (Shevach, 2009). Additional to IL-35, galectin-1 
is another candidate that plays a role in Treg mediated in vitro suppression. Galectin-1 
is a member of a highly conserved family of β-galactoside binding proteins, which is 
involved in Treg-Teff or Treg- DC interactions (Garin et al., 2007). Galectin-1 protein 
is expressed preferentially in Treg cells and its expression is up-regulated on T cell 
receptor (TCR) activation. Blockade of galectin-1 protein markedly down-regulated the 
inhibitory functions of both human and mouse Treg cells. Also, Treg cells from 
galectin-1-deficient mice exhibited diminished Treg cell activity (Shevach, 2009). Thus, 
these findings suggest alternative factors which may alter Treg function when using 
αCD3/28 coated beads as stimulus of T cell activation in vitro. In future studies, further 
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investigation should focus on the role of these candidates, such as IL-35 and galectin-1, 
in mediating defective Treg function in the presence or absence of hBD-2. APCs can 
also be used to replace αCD3/28 coated beads as the stimulus of T cell activation to 
validate the effect of hBD-2 on Treg function in terms of Treg–APC interaction. 
 
More recently, Bruhs et al. (2015) demonstrated that hBD-3 induced human 
CD4
+
CD25
-
 T cells to express the Treg specific markers, FoxP3, CTLA4 and 
glycoprotein A repetition predominant (GARP), following 24hrs pre-incubation in vitro 
before activation. Their suppression assay using these hBD-3-pretreated CD4
+
CD25
-
 T 
cells suggested an increase in percentage suppression of proliferating responder cells 
compared to the non-treated CD4
+
CD25
-
 T cells (Bruhs et al., 2015). These findings 
suggest that the role of hBD-3 in Treg cell differentiation and function is to promote 
Treg function in the periphery. These results are clearly at odds with the results reported 
in this chapter and so the reasons for this should be explored. The differences may be 
caused by two reasons: Firstly, in the case of the study reported here, Teff cells and 
Treg cells were pre-treated with hBD-2 for 4hrs before activation in our function assay, 
while in the study of Bruhs et al., cells were pre-treated for 24hrs prior to setting up the 
suppression assay. Future studies should focus on effect of hBDs pre-treatment on 
CD4
+
CD25
-
 T cells for different periods of time. Secondly, the antibody-coupled beads 
used in Bruhs et al. study were preloaded with anti-CD3, anti-CD28 and anti-CD2, 
whereas in our assay, we used the beads only coupled with anti-CD3 and anti-CD28. 
CD2 signalling has been suggested to induce FoxP3 expression and enhance 
CD4
+
CD25
high
 Treg cell function (De Jager et al., 2009) as well as being able to down-
regulate the expression of Bim, a pro-apoptotic factor in Treg cells, thereby increasing 
the survival of Treg cells (Kashiwakura et al., 2013). In our study, we did not apply 
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anti-CD2 stimulation and this may have decreased the stability of the Treg population in 
our cultures. 
 
Figure 6.4 A proposed schematic model summarising the key findings in Chapter 6. A. 
the balanced Treg suppression can control the proliferation of Teff cells so as to inhibit 
pro-inflammation. B. hBD-2 pre-treatment can cause the impaired Treg function which 
may lead to pro-inflammation. C. hBD-2 pre-treatment can also cause enhanced 
resistance of Teff cells to Treg suppression. 
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6.4 Conclusion 
In this chapter, our data suggest that the treatment of human CD4
+
 T cells with hBD-2 
may cause repressed Treg ability to inhibit Teff proliferation. At the same time, we 
found that hBD-2 treatment also caused an increase in Teff cell resistance to Treg 
mediated immunosuppression in vitro thereby presenting evidence that the apparent loss 
of immunoregulatory function observed in our previous chapters in the presence of 
hBD2 may result from two different hBD-2 mediated effects occurring simultaneously. 
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Chapter 7: Microarray analysis of the transcriptome of 
human CD4
+
 T cells in the presence or absence of hBD-2 
 
7.1 Introduction 
In the previous chapters, we demonstrated that treatment of human CD4
+
 T cells with 
hBD-2 induced an up-regulation of the Treg subset following 18hrs in culture in vitro, 
but drove these expanded Treg cells to express RORγt by 42hrs in culture and to 
differentiate into a Th17-like phenotype. The results of our suppression assays 
suggested that treatment with hBD-2 caused Treg to be defective in their ability to 
mediate suppression of Teff leading to enhanced Teff cell proliferation in vitro. In 
addition, hBD-2 treated Teff cells were found to exhibit resistance to Treg suppression 
in vitro. These data suggest that treatment with hBD-2 may play a role in regulating 
human CD4
+
 T cell functions. However, the gene expression profile of human CD4
+
 T 
cells following hBD-2 treatment is yet to be characterised. In this chapter, using 
microarray analysis, we demonstrated the differences between the gene transcriptome 
profiles of purified human CD4
+
 T cells activated by αCD3/28 antibodies in the 
presence or absence of hBD-2. We also validated the microarray data using RT-PCR of 
several candidiate genes which were found to contribute to the difference in gene 
expression profile between hBD-2 treated and non-treated samples. 
 
7.2 Results 
7.2.1 hBD-2 regulates human CD4+ T cell gene expression at 18hrs and 42hrs. 
To investigate the transcriptional profile associated with CD4
+
 T cell activation in the 
presence or absence of hBD-2, we analysed the mRNA profile of in vitro stimulated 
human CD4
+
 T cells using whole exon expression microarrays. We performed Principal 
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Component Analysis (PCA) to compare the gene transcriptome profiles of purified 
CD4
+
 T cells activated by αCD3/28 antibodies in the presence of absence of 10μg/ml 
hBD-2 at18hrs and 42hrs post activation stimulus. Figure 7.1 shows the PCA result of 
samples including stimulated control (Stim Co.) and hBD-2 treated stimulated samples 
(hBD-2 treated). First of all, in Figure 7.1 A2-6, samples are clearly separated into two 
groups using Principal component (PC) 1 which is the largest difference observed 
between transcriptomes following 18hrs and 42hrs cultures. This reflects the difference 
in the gene expression profiles between 18hrs (circle) and 42hrs (triangle) cultures, 
suggesting that the phenotypes of the cells following 18hrs in culture are quite distinct 
from the phenotypes of the cells following 42hrs in culture. However, in the case of 
PC2, we did not find any significant difference of clustering of samples between the two 
different time points. Interestingly, in the case of PC3 (Figure 7.1 C1-2, C3-6), although 
the samples randomly distribute in the plots, the 18hrs hBD-2 treated samples (red 
circles) are clearly separated from 18hrs Stim Co. samples (black circles). Whilst not 
being significant, this reflects a trend towards differences between the gene expression 
of Stim Co. and hBD-2 treated samples. In addition, samples co-incubated with hBD-2 
for 42hrs (red triangles) grouped and separated from 42hrs Stim Co. samples (black 
triangles) in PC6 (Figure 7.1, F1-5), suggesting differences in gene expression between 
Stim Co. and hBD-2 treated samples following 42hrs culturing. However, neither of 
these components can significantly distinguish samples according to different treatment 
and time points, as there are overlaps between groups (Figure 7.1, C6 and F3). 
Therefore, 18hrs samples and 42hrs samples need to be analysed separately to identify 
differentially expressed candidate genes in hBD-2 treated and non-treated cells at 
different time points. 
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Figure 7.1 PCA analysis of all stimulated samples. Human CD4
+
 T cells were isolated 
and activated using αCD3/28 antibodies in the presence or absence of hBD-2 (10µg/ml). 
After 18hrs and 42hrs culturing, RNA samples were purified and gene expression 
analysed using Affymatrix microarray. A-F and 1-6 represent the 2 dimensions of the 
PCA results and help to identify the individual graphs in the PCA results. The solid grey 
ovals are used to highlight the samples clustered in Comp3 and the dash grey ovals are 
used to highlight the samples clustered in Comp6. 
 
To identify the genes that are differently expressed in hBD-2 treated and non-treated 
cells, samples from 18hrs and 42hrs were analysed using PCA separately. Figure 7.2 
shows the PCA results using 18hrs Stim Co. and hBD-2 treated samples. It is found that 
the hBD-2 treated samples were distinguished from Stim Co. samples in PC2 which 
exhibits 42% variability, rather than in PC1 or PC3. This reflects the fact that the 
transcriptome of hBD-2 treated samples is distinct from the transcriptome of Stim Co. 
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samples and the candidate genes in PC2 contribute to this variation. Then, we analysed 
the samples cultured for 42hrs using PCA and the result showed that the hBD-2 treated 
samples separated from Stim Co. in PC3 which has 35% variability, but not in PC1 or 
PC2  (Figure 7.3). This suggests that the genes pulled out in PC3 contribute to the 
different expression profile in hBD-2 treated cells from Stim Co. cells.  
 
Figure 7.2 PCA results of stimulated samples at 18hrs. The black circles represent the 
two samples of stimulated control, and the red circles represent the two samples of 
hBD-2 treated samples. Samples are clearly separated by their treatment conditions in 
the Comp 2, suggesting that the genes in this component contribute to the difference of 
transcriptome profiles between hBD-2 treated and non-treated samples. A, B, C and 1, 2, 
3 represent the 2 dimensions of the PCA results and help to identify the individual 
graphs in the PCA results. 
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Figure 7.3 PCA results of stimulated samples at 42hrs. The black circles represent the 
two samples of stimulated control, and the red circles represent the two samples of 
hBD-2 treated samples. Samples are clearly separated by their treatment conditions in 
the Comp 3, suggesting that the genes in this component contribute to the difference of 
transcriptome profiles between hBD-2 treated and non-treated samples. A, B, C and 1, 2, 
3 represent the 2 dimensions of the PCA results and help to identify the individual 
graphs in the PCA results. 
 
In order to further characterise gene expression profiles in the hBD-2 treated samples 
compared to the non-treated control samples, we used GeneSpring GX 13.1 software to 
normalize the microarray data and perform statistical analysis. The results were 
summarized as a gene list of 24 candidates that were transcriptionally regulated by 
hBD-2 treatment (Figure 7.4, Appendix 7.1). These genes were found to be differently 
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expressed by fold change greater than 1.5, which is considered as biologically relevant. 
The functions of these genes include RNA binding in mitochondria (Mt-td, Mt-tm), 
DNA replication (Hist1h2aa, Cdrt15l2), cell apoptosis (Ddx46), NFκB signalling 
(Tnip3), chemoattraction (Ccl1), non-coding RNA (Rasa2-it1) and pseudogenes (Rnu4, 
Rnu6. Amongst these genes, we found that chemokine C-C motif ligand 1 (Ccl1) was 
down-regulated in hBD-2 treated CD4
+
 T cells. As discussed in Chapter 6, we 
demonstrated that the co-incubation of CD4 T cells with hBD-2 induces defected Treg 
suppressive function. Thus, we hypothesized that genes involved in Treg function may 
be differently expressed in hBD-2 treated samples at 18hrs or 42hrs. When we looked at 
particular genes, we found that both Ccl1 and Ctla4 contributed to the variation 
observed between treated and untreated samples at 18hrs post activation stimulus in 
PC2 (Figure 7.5 A). This indicates that both these genes were differently expressed 
between hBD-2 treated and untreated CD4
+
 T cells. Further verification of these results 
was performed using qPCR which shows that expression of both Ccl1 and Ctla4 was 
down-regulated following 18hrs in culture of hBD-2 treated samples relative to the 
untreated control (Figure 7.5 C and D). It has been reported the neutralization of CCL1 
can inhibit Treg suppressive function but not compromise Teff function (Hoelzinger et 
al., 2010). Additionally, Treg expression of CTLA-4 was necessary for immune 
suppression and prevention of in vivo autoimmunity (Tai et al., 2012, Bilate and 
Lafaille, 2012, Josefowicz et al., 2012). Therefore, these data suggest that the in vitro 
co-culturing with hBD-2 may induce down-regulation of both Ccl1 and Ctla4 gene 
expression in human CD4
+
 T cells which leads to defective ability to meditate Treg 
suppressive function. 
 
In addition, we reported in previous chapters that hBD-2 treatment of CD4 T cells 
induced RORγt expression at 42hrs, indicating that hBD-2 may promote polarisation 
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towards a Th17-like CD4
+
 T cell phenotype. In our ELISA data, it suggested that hBD-
2 treatment of CD4 T cells hardly induced both IL-6 and IL-17 production upon 
αCD3/28 stimulation. This indicates that there might be other pathways to enhance and 
maintain RORγt expression in the presence of hBD-2. Accordingly, IL-21 is able to 
induce RORγt expression in the absence of IL-6 (Muranski and Restifo, 2013, Korn et 
al., 2009). Therefore, we looked into our microarray data and found that Il21 gene 
expression contributed to the variation of hBD-2 treated samples and the control 
samples (Figure 7.5 A). Further validation using qPCR shows that hBD-2 induced Il21 
gene expression following 18hrs in culture (Figure 7.5 E).  These data indicate that even 
though hBD-2 did not induce IL-6 production, it could up-regulate IL-21 expression 
which in turn might increase the level of RORγt expression. However, because Il23r 
mRNA expression was not significantly changed (Figuer 7.5 F), this suggests that hBD-
2 may not induce a stable Th17 cell polarization and subsequent differentiation of 
pathogenic Th17 cells, as the stability and expansion of pathogenic Th17 requires IL-
23R expression (Muranski and Restifo, 2013, Lee et al., 2012). This is consistent with 
our finding in Chapter 5 that the co-incubation with hBD-2 did not induce IL-17 
production in vitro. 
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Figure 7.4 Heatmap of 24 genes whose expression changed more than 1.5 fold 
following 18hrs hBD-2 treatment. Statistical analysis was performed using Student t test 
and p value less than 0.01 was considered as significant. High scores (reds) correspond 
to up-regulated, and low scores (blues) correspond down-regulated genes in hBD-2 
treated CD4
+
 T cells (Stim + hBD-2) when compared with the non-treated samples 
(Stim Co.). 
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Figure 7.5 PCA analysis of genes regulated by hBD-2 treatment. A and B. PCA shows 
the genes that contribute to the components which make the samples distinct between 
Stim Co. and hBD-2 treated samples. C-F. qPCR validation of genes isolated from PCA 
analysis. Data were collected from 5 independent experiments (n=5). 
 
7.2.2 Preliminary results of qPCR indicate that certain genes are differently 
expressed in hBD-3 treated human CD4
+
 T cells relative to the untreated control. 
To investigate whether there is similar regulation of gene expression in human CD4
+
 T 
cells treated with hBD-3, one set of RNA samples were purified from CD4
+
 T cells 
cultured together with or without hBD-3. The preliminary data obtained shows that 
treatment with hBD-3 may induce a decrease of Ccl1 expression (Figure 7.5 A). This 
effect is similar to that observed following treatment of CD4
+
 T cells with hBD-2 
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(Figure 7.4 B). However, interestingly, we found a trend of increase of Ctla4 gene 
expression in the presence of hBD-3, which is the reverse effect to that observed 
following treatment with hBD-2. This is consistent with our flow cytometry data 
indicating an up-regulation of intracellular CTLA-4 expression in CD4
+
CD127
-
CD25
+
 
subset following co-culture with hBD-3. These data suggest that treatment with hBD2 
and hBD3 may induce different effects on CD4
+
 T cells. This may be due either to the 
cell being able to distinguish which hBD it is responding to thereby inducing a different 
set of signals in the target cell, or alternately that treatment with hBD3 delivers a more 
potent signal than treatment with hBD2. Moreover, the qPCR results show that there 
was up-regulation of Il21 expression following 18hrs and 42hrs in culture (Figure 7.5 
C). This finding indicates that treatment with hBD-3 may up-regulate IL-21 expression 
which in turn may induce Th17 differentiation. This is similar to our finding in hBD-2 
treated cells (Figure 7.4 C). However, interestingly, unlike hBD-2, co-incubation with 
hBD-3 also up-regulated Il23r expression following 18hrs in culture, and this trend 
increased following 42hrs in culture (Figure 7.5 D). These data suggest that treatment 
with hBD-3 may induce the expression of IL-23R which leads to a number of 
downstream events, including stabilization of Th17 polarization, pathogenic Th17 
differentiation and IL-17 cytokine production. These possibilities are consistent with the 
ELISA data presented in Chapter 5 in which treatment with hBD-3, but not hBD-2, 
induced up-regulation of IL-17 secretion by CD4
+
 T cells following 42hrs in culture. 
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Figure 7.6 Preliminary results of qPCR showing genes differently expressed in hBD-3 
treated human CD4
+
 T cells (n=1). 
 
7.3 Discussion 
In previous chapters, we reported the effect of hBD-2 and hBD-3 treatment on human 
CD4
+
 T cell activation and differentiation. Our data  presented in this thesis 
demonstrated that treatment of CD4
+
 T cells with hBD-2 and hBD-3 induced CD4
+
 T 
cell activation by up-regulating the expression of CD69 and CD25 at 18hrs and 42hrs 
following an activation stimulus. We also reported that co-culturing of CD4
+
 T cells 
with hBD-2 or hBD-3 induced Teff cells to differentiate towards a Th1/17-like 
phenotype by 18hrs post-activation stimulus and towards a Th17-like phenotype at 
42hrs post-activation stimulus. In addition, our Treg suppression assay showed that 
hBD-2 treatment lead not only to Tregs with defective function but also Teff cell 
exhibiting resistance to Treg mediated suppression. However, the regulation of target 
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gene expression of CD4
+
 T cells following treatment with hBDs is still not well 
understood. 
 
In this chapter, we use the microarray study to investigate the transcriptome profile of 
αCD3/28 stimulated human CD4+ T cells in the presence or absence of hBD-2. Our 
PCA analysis revealed that variation in certain components reflected the different gene 
expression in hBD-2 treated CD4
+
 T cells relative to the untreated control. This is the 
first time that the CD4
+
 T cell transcriptome profile was shown to be differently 
expressed following treatment with hBD-2.  
 
The PCA data and qPCR data presented here demonstrated that treatment with hBD-2 
induced down-regulation of Ccl1 and Ctla4 expression but up-regulated Il21 expression 
in vitro. In addition to hBD-2, our preliminary data shows that treatment with hBD-3 
may have a similar effect as hBD-2 in the down-regulation of Ccl1 expression but 
interestingly, causes an up-regulation of expression of Ctal4, Il21 and Il23r. It has been 
reported that hBD-2 and hBD-3 play a role in the pathophysiology of colitis and colitis-
associated microflora (Ho et al., 2013). Our data presented here has important 
consequences for understanding how the expression of hBD-2 and 3 is involved in the 
regulation of gene expression in CD4
+
 T cells which in turn may drive the CD4
+
 T cell 
intrinsic pro-inflammatory response. Our findings suggest that hBD-2 may down-
regulate Ccl1 gene expression at 18hrs post activation stimulus. CCL1 has been 
reported to play a role in mediating Treg suppressive function and anti-CCL1 treatment 
has been developed as a tumour immunotherapy by which the suppressive function of 
tumour-associated Treg cells can be inhibited in order to enhance the Teff cell immune 
response against cancer cells (Hoelzinger et al., 2010). The down-regulation of CCL1 
gene expression by hBD-2 may be the cause of the observed defective Treg function. 
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Additionally, we reported that treatment with hBD-2 may also down-regulate CTLA-4 
mRNA expression in vitro. CTLA-4 interacts with co-stimulatory molecules 
CD80/CD86 on APCs to down-regulate or prevent T cell co-stimulation signalling 
pathway (Shevach, 2009). This mechanism is involved in Treg–mediated suppression, 
in addition to its important cell intrinsic role in limiting responses of activated T cells 
and the role of CTLA-4 in maintenance of homeostasis can be significantly modified by 
the genetic background(Josefowicz et al., 2012). Thus, the down-regulation of CTLA-4 
expression in the presence of hBD-2 may reflect the impaired ability of Treg cells 
interaction with APCs, leading to defective Treg suppressive function. 
 
In addition, it is the first time that an up-regulation of Il21 expression in the presence of 
hBD-2 has been reported. IL-21 has been reported to be involved in driving Th17 
lineage development (Korn et al., 2009). At the early stage of Th17 development, IL-21 
is secreted by early Th17 cells and thus performs a „self-amplification autocrine loop‟ 
via the IL-21 receptor. Its level of expression is also increased following  IL-1 
signalling (Muranski and Restifo, 2013). Our data suggested that hBD-2 treatment 
caused an increase of Il21 mRNA expression. This may reveal the fact that treatment 
with hBD-2 could potentially encourage the early Th17 development. However, Th17 
polarization requires IL-23/IL-23R signalling to maintain the stability of Th17 lineage 
which is important for the matured Th17 cells (Korn et al., 2009). Interestingly, we did 
not find significant change of Il23r expression level in hBD-2 treated CD4
+
 T cells 
compared the non-treated control, but the preliminary data on hBD-3 treated cells 
showed an up-regulation of Il23r expression level. These findings may suggest that 
Th17 polarization induced in the presence of hBD-2 may not be as stable as that 
induced following treatment with hBD-3, leading to the immature Th17 phenotype. 
This is consistent with our IL-17A ELISA data indicating that hBD-3, but not hBD-2, 
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induced IL-17A production in CD4
+
 T cells. We also found that hBD-3 treatment could 
enhance Il23r expression. Il23r is reported to play an essential part in the development 
of pathogenic Th17 cells (Lee et al., 2012). This suggests that compared to hBD-2, 
hBD-3 alone may be capable of inducing the pathogenic phenotype of Th17 cells. 
In addition, we also found that the expression of some other genes were differently 
regulated in hBD-2 treated human CD4+ T cells which have been confirmed to be 
associated with RNA binding in mitochondria (Mt-td, Mt-tm), DNA replication 
(Hist1h2aa, Cdrt15l2), cell apoptosis (Ddx46), NFκB signalling (Tnip3), non-coding 
RNA (Rasa2-it1) and pseudogenes (Rnu4, Rnu6). Interestingly, Tnip3 was found to be 
up-regulated by hBD-2 treatment. TNIP3 is reported to be a negative regulator of NF-
κB signalling, which is also involved in the signalling events downstream of TNF-α and 
in particular in the regulation of NF-κB signalling(Nair et al., 2009, Vereecke et al., 
2009). Recent studies reported that TNIP3 was found to be up-regulated in Crohn‟s 
Desease biopsies (Noble et al., 2010) and psoriasitic skin lesions (Johnston et al., 2013). 
This suggests that hBD-2 up-regulated TNIP3 expression which may in turn suppress 
NF-κB signalling leading to the blockade of IL-17A cytokine production. Moreover, 
our findings suggest the involvement of epigenetic regulation, such as regulation of the 
His1h2aa.His1h2aa gene which encodes a replication-dependent histone which is a 
member of the histone H2A family. The role of this gene in human T cell function is 
still not well understood. It is reported that the down-regulation of His1h2aa is co-
related with the development of necrotizing enterocolitis in neonatal mice, suggesting 
the association with pro-inflammatory conditions (Jung et al., 2015). Further validation 
of these targets need to be done in future studies. 
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Figure 7.7 A proposed schematic model summarising the key findings in Chapter 7. A. 
CCL1 contributes to the maintenance of Treg function. Down-regulation of CCL1 by 
hBD-2 or hBD-3 may lead to the impaired Treg suppression. B. the difference between 
hBD-2 and hBD-3 treatment in vitro. hBD-2 induces CD4
+
 T cells to produce IL-21 and 
differentiate to become RORγt+ T cells. However, the lack of IL-6 induction limits the 
production of IL-17A. In contrast, hBD-3 induces both IL-6 and IL-21 which can, in 
turn, promote IL-17A production, leading to pro-inflammation. Preliminary data 
suggests an up-regulation of IL23r gene expression following the treatment of hBD-3, 
this finding will require further characterisation in future studies. 
 
7.4 Conclusion 
In this chapter, we demonstrated that hBD-2 treatment of CD4
+
 T cells regulated gene 
expression following αCD3/28 treatment for 18 and 42hrs in vitro. Our microarray data 
revealed chemokine Ccl1 as a potential target gene product responding to hBD-2 
treatment. The blockade of CCL1 has been reported to inhibit Treg suppressive function. 
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Further investigation of gene expressions using qPCR revealed that hBD-2 treatment 
also down-regulated Ctla4 expression and up-regulate Il21 expression, suggesting a role 
for hBD-2 in regulating CD4
+
 T cell plasticity and Treg function, which is consistent 
with the results of our polarization and function studies presented in previous chapters. 
In addition, our preliminary qPCR data showed the different patterns of expression in a 
number of key target genes in hBD-3 treated CD4
+
 T cells compared with hBD-2 
treated cells. 
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Chapter 8: General Discussion and Future Directions 
 
8.1  General discussion 
We initially demonstrated in Chapter 3 that co-culture of human PBMCs with hBD-2 
together with anti-CD3/28 caused an up-regulation in numbers of CD69
+
CD25
+
 T cells 
by 18hrsand these numbers remain increased following 40hrs in culture. 
Characterisation of FoxP3 expression also revealed an up-regulation of this 
transcription factor in the CD4
+
CD25
high
 T cell subset. These data are consistent with 
published findings which reveal that mBD-14, an ortholog of hBD-2, is capable of 
inducing CD4
+
CD25
-
 T cells differentiate into CD4
+
CD25
+
 Tregs in mice(Navid et al., 
2012). We also observed that expression of FoxP3 is significantly reduced following 
42hrs in culture following treatment with 10ug/ml of hBD-2 in these same 
CD4
+
CD25
high
 T cells. It has been suggested that the diminished FoxP3 expression in 
CD4
+
CD25
high
 Tregs may diminish their suppressive ability. Thus, we analysed T cell 
proliferation using CFSE stained PBMCs and revealed that hBD-2 treatment enhances 
the proliferation of CD4
+
 T cells and CD8
+
 T cells in vitro following 72hrs and 96hrs, 
suggesting that there may be a defect in the ability of treated Tregs to suppress Teff 
proliferation. However, this did not rule out the possibility that treatment with hBD-2 
may induce the resistance of Teffs to regulation by Tregs. In addition, we observed an 
increase of the CD69
+
CD25
-
CCR6
+
 T cell population but not CD69
+
CD25
-
CCR6
-
 T cell 
population in the presence of hBD-2 or hBD-3 at 18hrs. This suggested that co-culture 
with hBD-2 or hBD-3 either enhanced CCR6 expression in early activated CD69
+
CD25
-
 
T cells or that the CCR6
+
 cells were specifically responding to treatment with hBD2. 
Interestingly, this effect was not maintained at 42hrs. By 42hrs, only 
CD69
+
CD25
+
CCR6
-
 and CD69
-
CD25
+
CCR6
-
 subsets appeared to respond to hBD-2 
and hBD-3 suggesting that there may have been some degree of apoptosis induced in 
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the CCR6
+
 cells. Alternatively, as both of the responding subsets observed at 42hrs are 
CCR6
-
 cells, it may suggest that there are alternative receptors or pathways by which 
hBD-2 and hBD-3 may induce CD4
+
 T cell activation by hBD-2 and hBD-3 that are 
independent of expression of CCR6. 
 
In the following chapter, Chapter 4, we moved away from the use of mixed cells and 
focussed on purified CD4
+
 T cells in order to investigate whether or not the observed 
effects were intrinsic to CD4
+
 T cells or required the presence of another cell type. We 
demonstrated that co-culture of purified T cells with hBD-2 and hBD-3 together with an 
activation stimulus mediated by αCD3/28 continued to induce an increase in the 
presence of CD69
+
CD25
+
 and CD69
-
CD25
+
 subsets at both 18hrs and 42hrs post 
activation stimulus. Additionally, we observed that by 96hrs post stimulus there was an 
increase in CD4
+
 T cell proliferation in the presence of hBD-2 and hBD-3 as had been 
observed in the mixed cell cultures. Analysis of IL-2 secretion by purified T cells using 
ELISA shows that addition of hBD-2 and 3 to cultures induces increased IL-2 
production by CD4
+
 T cells in vitro. These elevated levels of IL-2 may promote the 
increased levels of T cell proliferation mentioned above. Characterisation of 
intracellular FoxP3 expression showed an increase in FoxP3 expression in CD4
+
CD127
-
CD25
+
 Tregs following co-incubation of hBD-2 or hBD-3 for 18hrs. These data 
suggested that co-culture with hBD-2 and hBD-3 may induce Treg differentiation by 
18hrs in vitro. However, this effect is apparently reversed by 42hrs in culture. At this 
later time point, we found that FoxP3 expression decreased in the CD4
+
CD127
-
CD25
+
 
Treg population. These data indicate that Treg suppressive function may be potentially 
defective following the co-incubation of purified T cells with either hBD-2 or hBD-3 
for 42hrs in vitro due to the apparent loss of FoxP3 expression. It has been extensively 
demonstrated in the literature that Treg-mediated suppression of Teff cell activation and 
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proliferation depends on the stability of FoxP3 expression within the Treg compartment, 
especially in conditions using αCD28 for co-stimulation in vitro. Thus, the data 
presented in this chapter demonstrate a role for hBD-2 and 3 in driving human CD4
+
 T 
cell activation and proliferation. These results also reveal that co-incubation of T cells 
with hBD-2 and 3 in vitro may exert an effect on Treg cell function and, possibly, 
plasticity thereby reducing the ability of Treg cells to mediate their suppressive function 
and, as a consequence, allowing for an increase in activation and proliferation.  
 
Recent studies have demonstrated that hBD-2 treatment in vitro induces cytokine 
production in human CD3
+
 T cells (Kanda et al., 2011). In the presence of hBD-2, 
secretion of IFN-γ was found to be up-regulated in the activated CD3+ T cells using 
αCD3/28 (Kanda et al., 2011), suggesting that hBD-2 may promote a Th1 polarizing 
environment. Thus, we hypothesized that hBD-2 may push CD4
+
 T cells to differentiate 
towards a Th1 phenotype and away from a Treg phenotype. In Chapter 5, we 
characterised the role of hBD-2 and hBD-3 in driving human CD4
+
 T cells polarisation. 
Our in vitro data suggests that treatment with hBD-2 and hBD-3 can not only induce 
Teff differentiation into RORγt+T-bet+ (Th17/Th1) cells, but can also trigger the 
differentiation of regulatory T cell (Treg) expressing RORγt and T-bet rather than the 
master controller of Treg function, FoxP3. This apparent plasticity of T cell phenotype 
allowing them to convert from Treg to Th1/17-like effector T cell occurred following 
18hrs in culture and in the presence of the activation stimulus provided by αCD3/28. 
Interestingly, by 42hrs in culture, treatment with hBD-2 and hBD-3 induced both Teff 
cell and Treg cell differentiation towards the Th17-like phenotype. Compared with 
treatment with hBD-2, treatment with hBD-3 induced a more pronounced effect in 
terms of Treg cells expressing increased levels of RORγt in CD4+ T cells. This elevated 
expression may, in turn, be responsible for the induction of higher IL-17A secretion. 
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Consistent with this idea, it was found that treatment with hBD-3 but not hBD-2 was 
capable of inducing the higher level of secretion of IL-17A. Additionally, treatment 
with hBD-3 induced an increased expression of IL-6. IL-6 is a cytokine, which is 
described as having the ability to drive the differentiation of naïve T cells to IL-17 
secreting Th17 cells. Thus, this study explored the function of hBD-2 and hBD-3 in 
regulating CD4
+
 T cell plasticity which could potentially result in altered Treg and Teff 
cell differentiation and function.  
 
It is of interest that a number of papers have been published documenting a loss of 
FoxP3 in Tregs in the clinical environment such as in the case of psoriasis (Soler and 
McCormick, 2011, Joller and Kuchroo, 2014, Lowes et al., 2014). Psoriasis is a chronic 
inflammatory skin disease mediated by T cells and dendritic cells. Activated T cells 
contained within psoriatic lesions discretely secrete IFN-γ, IL-17 and IL-22, suggesting 
that Th1 and Th17 cells are involved in the development of pathology of psoriasis 
(Lowes et al., 2014). Clinical studies showed that Tregs isolated from patients with 
psoriasis appeared to exhibit an enhanced RORγt expression whilst simultaneously 
losing FoxP3 expression. These cells were capable of differentiating to become IL-17A-
secreting cells on ex vivo stimulation (Bovenschen et al., 2011). It has also been 
suggested that the numbers of both FoxP3
+
 Treg cells and Th17 cells are increased in 
patients with psoriasis, however, the suppressive function of Treg cells in these patients 
was found to be decreased (Furuhashi et al., 2013, Zhang et al., 2015), indicating the 
dysfunction of Tregs under these inflammatory conditions. Accordingly, FoxP3
+
 Tregs 
in psoriatic lesions can be induced to differentiate to become FoxP3 and RORγt dual-
expressing cells that converge on the IL-17-expressing Tregs, potentially polarizing in 
certain situations towards the pathogenic Th17 lineage (Soler and McCormick, 2011). 
Interestingly, the IL-17-expressing Tregs were still found to display potent suppressive 
113 
 
function as well as the expression of IL-17. The presence of Tregs in the skin is 
beneficial to the maintenance of the balance between host immunity and commensal 
bacteria under non-pathogenic conditions (Mercer et al., 2014). However, under 
pathogenic conditions, such as in the case of psoriasis, IL-23, expressed in the inflamed 
lesion can down-regulate FoxP3 expression and promote Treg cells to differentiate into 
pathogenic Th17 cells (Soler and McCormick, 2011, Lowes et al., 2014), leading to 
chronic inflammation. Our data presented in this chapter demonstrated that upon 
treatment of hBD-3, CD4
+
 T cells may become dual expressing Treg cells with the 
induction of RORγt expression in the FoxP3+ Treg population. There is also a 
simultaneous enhancement of IL-17A secretion. These findings lend support to the 
hypothesis that treatment with hBD-2 and 3 may cause aberrant polarisation of the T 
cell compartment leading to the onset of pathology associated with psoriasis. 
 
The level of IL-6 was also found increased in the hBD-2 treated CD3
+
 T cell culture 
activated by αCD3/28 co-stimulation, whilst the level of IL-17 decreased (Kanda et al., 
2011). However, in CD4
+
 T cell culture treated with hBD-2, we did not find significant 
change of the levels of IL-6 and IL17. Because CD3
+
 T cell population includes CD4
+
 T 
cells, CD8
+
 T cells, NKT cells and HLA DR
+
 T cells (Orru et al., 2013), it is possible 
that the other T cell subsets can respond to hBD-2 treatment to secret IL-6 but also 
induce an alternative pathway to restrict Th17 differentiation to limit IL-17 production. 
Future studies should investigate the effect of hBD-2/3 treatment on cytokine 
production by non-CD4
+
 T cells, such as CD8
+
 cell cytokine production. 
 
As we had reported the loss of FoxP3 expression and the gain of RORγt expression in 
CD4
+
 T cells by 42hrs in the presence of hBD-2, we hypothesized that treatment with 
hBD-2 may cause Treg cells to lose their suppressive function as they lose expression of 
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FoxP3 and as a consequence will not be able to control Teff proliferation. Additionally, 
with the emergence of RORγt+ Teff cells, these effector T cells may become resistant to 
the suppressive action of Tregs. Thus, in this chapter, we aimed to test these two 
possibilities in vitro by culturing together FACS-sorted Treg (CD4
+
CD127
-
CD25
+
) and 
Teff (CD4
+
CD127
+
CD25
-
) cell populations isolated from human peripheral blood 
samples. Our data suggested that treatment of Treg cells with hBD-2 may dampen down 
their ability to induce suppression of Teff cell activity. Interestingly, co-culture with 
hBD-2 would also appear to increase Teff cell resistance to Treg immunoregulation in 
vitro. 
 
The data reported so far suggests that hBD-2 has the capacity to regulate human CD4 T 
cell differentiation and so it became important to try to characterise some of the 
molecular events that mediate this regulation. 
 
To this end, we performed microarray gene analysis in order to investigate the 
difference between the transcriptome profile of stimulated human CD4
+
 T cells with or 
without treatment of hBD-2. This analysis demonstrated, firstly, that Ccl1 is a potential 
gene responding to hBD-2 treatment. The neutralization of CCL1 has been reported to 
inhibit Treg communication to Teff cells, leading to the reduced suppressive function in 
tumour-associated Treg cells (Hoelzinger et al., 2010). The down-regulation of this 
gene by hBD-2 treatment may therefore be involved in mediating the impaired 
suppressive function of Treg cells in our in vitro culture. Secondly, further analysis 
using principle component analysis (PCA) followed by validation using qPCR 
demonstrated that hBD-2 treatment down-regulated Ctla4 gene expression in CD4
+
 T 
cells whilst up-regulating Il21 gene expression. These results are consistent with our 
findings that hBD-2 regulates Treg function and Th17 differentiation. In contrast to 
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hBD-2 treated cells, the preliminary data from hBD-3 treated cells revealed a different 
pattern of gene expression which shows that hBD-3 may also up-regulate Il23r gene 
expression, leading to a pathogenic Th17 phenotype differentiation. 
 
8.2  Future directions 
8.2.1  Using naïve T cells 
In the periphery, naïve T cells are activated and polarized in response to their cognate 
antigen to become different subsets, such as Th1, Th2, Th17 and Treg cells (Lazarevic 
et al., 2013). In our experiments, we used purified CD4
+
 T cells, which include memory 
T cells, naïve T cells as well as Treg cells. This mimics the in vivo conditions in the 
periphery when T cells are involved in immune response. However, memory T cells are 
antigen experienced T cells which can be activated more quickly and become matured 
effector T cells. The response by these memory T cells therefore can alter the 
differentiation and plasticity of naïve T cells by changing the cytokine components in 
the cell culture. Because of the variation in human peripheral T cell samples, the 
memory T cells compartments from each participant will have different antigen 
experience. In future studies, we could focus on purified naïve T cells in order to 
characterize more effectively the differentiation and plasticity of only naïve CD4
+
 T cell 
subsets in the presence of hBDs. The characterization of naïve T cell differentiation can 
be performed using single-cell RNA sequencing in order to profile the transcriptome in 
different subsets from the heterogeneous T cell population. 
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8.2.2  Further investigation on CCL1 signaling 
Our microarray data suggested that expression of CCL1 was down-regulated in the 
presence of hBD-2 which may lead to the impaired Treg-mediated immunosuppression 
of Teff proliferation. Future studies should further characterise whether hBD-2 and 
hBD-3 treatment can also reduce the level of CCL1 secretion in to the cell culture. In 
addition to the detection of secreted CCL1, it would be interesting to know if this 
defective Treg function can be prevented or overcome by CCL1 treatment, and it is 
equally important to clarify the mechanisms and the factors involved in the down-
regulation of Ccl1 expression by hBD-2. This information can help to develop novel 
therapeutic agents to restrict the symptoms in a number of autoimmune diseases in 
which overexpression of hBDs have been reported, such as psoriasis. 
 
Interestingly, the neutralization of CCL1 has been reported to be a potential therapy to 
limit Treg suppression in cancer immunity (Hoelzinger et al., 2010), hBD-2 and hBD-3 
treatment may provide an alternative pathway to down-regulate CCL1 production in 
order to deactivate Treg cells and promote the effector T cell response. In vivo studies 
focusing on the effect of hBD-2 and 3 on T cell development in experimental models of 
cancer, such as melanoma, could be investigated. These experimental mouse models 
could be treated with defensins to see if the tumour development is inhibited. In 
addition to the control of cancer cell proliferation, Treg development should also be 
investigated at the same time. β-defensin knockout mice could be an important model to 
investigate the role of defensins in tumour immunology. 
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8.2.3 Further validation of the other genes found in Microarray analysis 
Besides Ccl1, we also found other genes differently regulated in hBD-2 treated human 
CD4+ T cells. Some of them are involved in the biological process, including RNA 
binding in mitochondria (Mt-td, Mt-tm), DNA replication (Hist1h2aa, Cdrt15l2), cell 
apoptosis (Ddx46), NFκB signalling (Tnip3), non-coding RNA (Rasa2-it1) and 
pseudogenes (Rnu4, Rnu6). Although the roles of these genes in human T cells are still 
not clear, further investigation should be expanded in order to validate the expression of 
these genes after hBD-2 or hBD-3 treatment using RT-PCR. 
 
8.2.4  Characterization of β-defensins using in vivo models 
In this project, our experiments were performed using an in vitro system. So, we should 
ask the question whether we would observe a similar effect in vivo and how both sets of 
data could be applied to the understanding of the mechanism of actions of hBD-2 and 3. 
In vivo, T cells are activated by interacting with MHC-antigen complexes expressed on 
APCs. The participation of APCs could result in different effects being mediated from 
those observed using αCD3/28 activation, because Treg can also interact with APCs to 
inhibit their activities and the secretion of IL-10 by Tregs can limit the level of 
inflammation occurring in local tissues. However, these processes will not be 
recapitulated in our in vitro cell cultures. Therefore, we can speculate that, using an in 
vivo system, following β-defensin treatment, the induction of FoxP3+ Treg phenotype 
by hBD-2 or hBD-3 might be prolonged or more stable than that observed using our in 
vitro cultured Tregs. Indeed, recent studies by Navid et al. (2012) and Bruhs et al. 
(2015) using mBD-14 verify that in vivo treatment of mBD-14 induced the Treg-
mediated suppression of contact hypersensitifity (CHS) and experimental autoimmune 
encephalomyelitis (EAE), respectively. Additionally, our data collected at 42hrs may 
reflect a scenario whereby there is chronic inflammation induced in which the inflamed 
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epithelial tissue is continuously secreting β-defensins. The extended treatment of hBD-2 
or hBD-3 may lead to a more pro-inflammatory condition causing tissue damage and a 
higher secretion of IL-6. Thus, future studies could involve the use of animal models 
displaying more chronic inflammation, such as psoriasis or IBD to characterise the role 
of continuous secretion of hBD-2 and hBD-3. 
 
8.2.5  DefbΔ9/DefbΔ9 mice 
There are many murine β-defensin knockout models. The research group led by Prof. 
Julia Dorin from University of Edinburgh has developed a mouse model, so called 
DefbΔ9/ DefbΔ9 mice, in which the whole cluster of beta-defensin on chromosome 8 
containing 9 mouse β-defensins is knocked-out. Their recent studies mainly focus on 
the sperm dyfunction and infertility in KO mice. Because β-defensin genes are clustered 
in a group and respond to the stimuli at the same time, the loss of one beta-defensin can 
be compensated for by the presence of the other orthologs in the same clusters. 
Therefore, data collected from these knockout models may show no significant 
difference between the single gene knockout mice and the wild-type control (Navid et 
al., 2012). Thus, knocking out the whole cluster can solve this problem. Zhou et al. 
reported that the partial deletion of β-defensin cluster in chromosome 8 resulted in 
sperm dyfunction, suggesting the essential role of β-defensins in sperm maturation 
(Zhou et al., 2013, Dorin, 2015). However, very few studies have used this model in 
immunology related studies. Also, the knocking out of the whole cluster may create 
another possibility which is to identify the function of each individual beta-defensin 
gene, as each of the 9 beta-defensin peptides may be added back one by one. It would 
be of great interest to use this model to study the role of beta-defensin in the pathology 
of autoimmune disease. We could potentially induce psoriasis or IBD in this KO model 
119 
 
to see if the pathogenic symptoms can be limited or even worsened. Also, this model 
can be used to study β-defensin-induced T cell trafficking. 
 
8.2.6  Epigenetic/post-translational level study 
Epigenetic regulation in T cell differentiation and function is also a rapidly growing 
area of research. Treg function is strictly controlled by demethylation of CpG motifs in 
the TReg cell-specific demethylated region (TSDR) of the foxp3 locus to obtain the 
normal suppressive function. Recently, Bruhs et al. (2015) revealed that treatment with 
mBD-14 induces FoxP3 expression in CD4
+
CD25
-
 murine T cells via demethylation of 
the CpG sites of the foxp3 promoter.  
 
Additionally, the development of Treg lineage can be regulated by microRNAs. It is 
reported that microRNA-15b/16 can enhance Treg differentiation (Singh et al., 2015). 
Recent studies by Okoye et al. (2014) demonstrated that Treg cells can produce 
exosomes containing microRNA which are capable of suppressing the differentiation of 
pathogenic Th1 cells. It is interesting to identify whether hBDs can regulate these 
pathways to alter the translation of other genes which play a key part in Treg function, 
such as Ccl1. 
 
8.2.7  Allergy 
In Chapter 3, we demonstrated that hBD-2 and hBD-3 treatment resulted in the 
appearance of of T cells with a Th1-like phenotype following 18hrs in culture. This 
finding suggests that hBD-2 and hBD-3 may induce a bias microenvironment towards 
Th1 cell differentiation. This environment can also induce Th2 cells to differentiate into 
a Th1 phenotype. It has been demonstrated that allergen-specific Th2 cells are involved 
in the pathology of allergic diseases, such as asthma (Chung, 2015). It is worth 
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investigating whether this Th1 polarization effect induced by treatment with hBD2 can 
drive Th2 cells to differentiate into Th1 cells thus reducing the symptoms of these Th2-
mediated allergic diseases. 
 
8.3  Concluding remarks 
In conclusion, we demonstrated that the treatment of hBD-2 and hBD-3 in vitro induces 
human CD4
+
 T cell activation and proliferation in both whole PBMCs culture and 
purified CD4
+
 T cell culture. Additionally, our results reveal a role of hBD-2 and hBD-
3 in CD4
+
 T cell differentiation on the point of view of T cell plasticity. The presented 
data suggest that hBD-2 and hBD-3 treatment up-regulates the percentage of FoxP3
+
 
Treg in culture. However, the treatment of hBD-2 and hBD-3 is also capable of 
inducing T-bet and RORγt expression in both Treg cells and Teff cells, leading to Th1-
like and Th17-like phenotype differentiation. Compared with hBD-2, hBD-3 induced 
Treg expressing more RORγt which induces IL-17A expression. Our Treg suppression 
assay suggests that hBD-2 may dampen down Treg ability to suppress at the same time 
that it causes an increase in Teff resistance to Treg mediated immunoregulation in vitro. 
These findings reveal a role of hBD-2 and hBD-3 in the pathology of T-cell-derived 
autoimmune diseases, such as psoriasis. Further characterisation using the microarray 
assay revealed Ccl1 as potential target genes responding to hBD-2 treatment, providing 
a useful target for regulating hBD-2 related CD4
+
 T cell immune response or tissue 
inflammation. 
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Appendix 2.3  Quality Control of Affymatrix Microarray analysis 
 
The figure below shows the profile of hybridization controls analysed using GeneSpring 
GX 13.1 software. As it is shown in this figure, the profiles of 8 control probes are close 
and the curves of 4 samples are similar. The profiles reflect the staggered concentration 
of these 8 probes. The similarity of the curves indicate good hybridization and washing 
of the arrays. 
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Appendix 2.4  Calculation for qRT-PCR 
 
The figure below shows a worked example of the calculation of relative expression 
using the relative standard method. Standard curves are generated for both the gene of 
interest (in this example, Btk) and the house keeping gene, Hprt. The standard curve is 
shown below. A 1:10 serial dilution of the genes was carried out. The standard curves 
for both genes were generated by plotting the Ct values against the Log10 concentrations 
of the gene. 
 
 
 
The table below shows the average Ct value of the different samples. 
 
Sample Average Ct 
Hprt1 
Average Ct 
Ccl1 
Stim Co. 18hrs 21.96 25.42 
Stim + hBD-2 18hrs 21.36 26.22 
Stim Co. 42hrs 21.07 29.04 
Stim + hBD-2 42hrs 21.32 29.73 
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The equation obtained from the standard curve for Hprt1 and Ccl1 was used to calculate 
the gene concentration in the different samples The table below shows the mean value 
in Log10 of different samples from triplicates. 
Sample Concentration 
(Log10) 
Hprt1 
Concentration 
(Log10) 
Ccl1 
Stim Co. 18hrs 0.06 0.08 
Stim + hBD-2 18hrs 0.08 0.04 
Stim Co. 42hrs 0.10 0.01 
Stim + hBD-2 42hrs 0.09 0.01 
 
 
Relative gene expression in each sample was obtained by dividing the concentration of 
the gene of interest (Ccl1) by the housekeeping gene (Hprt1). The mean value of 
relative expression from triplicates is shown below. 
 
Sample Relative expression 
Ccl1 
Stim Co. 18hrs 2.06 
Stim + hBD-2 18hrs 0.89 
Stim Co. 42hrs 0.18 
Stim + hBD-2 42hrs 0.17 
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Appendix 2.5  Melting curve 
 
An additional programme for melting curve analysis was carried out in order to ensure 
the product of primer was the expected size and not the result of primer dimer. The 
image below shows an example of a melting curve. 
 
 
Figure 1. The image of melting curve. 
Changes in fluorescence (y axis) with increasing temperature (x axis) was detected. 
When the temperature increases, the two strands of the amplicon breaks to form single 
stranded DNA triggering the fluorescent intercalating dye to dissociate from the DNA 
and stop fluorescing. 
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Appendix 3.1  Gate stratergy for FoxP3 staining in CD4+CD25High T cells 
in human PBMCs. 
 
PBMCs were stained and analysed using flow cytometry. To exclude dead cells, a plot 
of forward scatter (FSC-A) vs. side scatter (SSC-A) plot was set at the beginning of 
analysis. Lower granularity on SSC-A and FSC-A indicates dead cells. Hence, the 
viable cells are gated on higher SSC-A and FSC-A signal (upper left). In a mixed cell 
population, to identify CD4+ T cells, CD4 was used as the first marker and it is plotted 
against the SSC gated in R1 (upper middle). Cells are then analysed for the expression 
of T cell activation markers, CD25 and CD69 in the CD4+ T cell gate (upper right). To 
identify Foxp3 expression, CD4+ T cells were gated with the CD25 (middle). The 
population was then separated into three fractions. The expression of Foxp3 in each 
fraction was analyzed (lower). As it is reported, higher amounts of Foxp3 expressed in 
CD4
+
CD25
High
 T cells (Bilate and Lafaille, 2012). Thus, we analyze Foxp3 expression 
in the fraction of CD4
+
CD25
High
 T cells. 
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Appendix 7.1  A table of 24 genes differentially expressed in hBD-2 
treated human CD4
+
 T cells at 18hrs. 
 
Transcripts 
Cluster Id 
Genes 
Regulation 
in hBD-2 
treated 
samples 
Fold 
change 
Genedescription 
17100659 Mt-td down -2.970 Mitochondrially encoded tRNA aspartic 
acid 
16843309 Ccl1 down -1.988 Chemokine (C-C motif) ligand 1 
17016296 Hist1h2aa down -1.550 Histone cluster 1, H2aa 
17100651 Mt-tm down -1.525 Mitochondrially encoded tRNA 
methionine 
16832227 Cdrt15l2 down -1.514 CMT1A duplicated region transcript 15 - 
like 2 
16786964 Unknown gene* up 1.517 Unknown 
16946426 Rasa2-it1 up 1.540 RASA2 intronic transcript 1 (non-protein 
coding), novel transcript 
17009424 Unknown gene* up 1.548 Unknown 
16989367 Ddx46 up 1.552 DEAD (Asp-Glu-Ala-Asp) box poly 
peptide 46 
17117545 Loc100131541 up 1.558 Unknown 
16792068 Unknown gene* up 1.571 Unknown 
16742636 Rnu6-126p up 1.600 RNA,U6 small nuclear 126, pseudogene 
16942038 Rnu6-1181p up 1.610 RNA,U6 small nuclear 1181, pseudogene 
16937793 Rnu6-377p up 1.614 RNA,U6 small nuclear 377, pseudogene 
16938269 Rnu4-85p up 1.634 RNA,U4 small nuclear85, pseudogene 
16703431 Unknown gene* up 1.640 Unknown 
16736266 Rnu6-593p up 1.690 RNA,U6 small nuclear 593, pseudogene 
16979444 Tnip3 up 1.692 TNFAIP3 interacting protein 3 
16770254 Unknown gene* up 1.721 Unknown 
17109675 Unknown gene* up 1.754 Unknown 
16979466 RNU6-948P up 1.847 RNA,U6 small nuclear 948, pseudogene 
16970859 RNU6-531P up 1.861 RNA,U6 small nuclear531, pseudogene 
16694232 Unknown gene* up 2.012 Unknown 
16914935 Unknown gene* up 2.021 Unknown 
* The information of the gene relevant to this probe ID has not been updated in the 
database (presented as “<N/A>” in Figure 7.4). 
